Multiple Sclerosis

New England Journal of Medicine
378, 169-180
DOI: 10.1056/nejmra1401483

Citation Report

#	Article	IF	Citations
1	Interferon-associated therapies toward HIV control: The back and forth. Cytokine and Growth Factor Reviews, 2018, 40, 99-112.	3.2	17
2	Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. Brain, 2018, 141, 1637-1649.	3.7	49
3	Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nature Reviews Neuroscience, 2018, 19, 283-301.	4.9	302
4	Healthcare resources utilisation in primary progressive multiple sclerosis. Neurological Sciences, 2018, 39, 1169-1174.	0.9	8
5	EBI2 â€“ Sensor for dihydroxycholesterol gradients in neuroinflammation. Biochimie, 2018, 153, 52-55.	1.3	14
6	Progressive brain rich-club network disruption from clinically isolated syndrome towards multiple sclerosis. NeuroImage: Clinical, 2018, 19, 232-239.	1.4	33
7	Multiple Sclerosis Functional Composite. Noropsikiyatri Arsivi, 2018, 55, S66-S68.	0.2	6
8	Clinical adverse effects of natalizumab. Medicine (United States), 2018, 97, e11507.	0.4	4
9	Information provision for people with multiple sclerosis. The Cochrane Library, 2018, 2018, CD008757.	1.5	27
10	Variant of EOMES Associated with Increasing Risk in Chinese Patients with Relapsing-remitting Multiple Sclerosis. Chinese Medical Journal, 2018, 131, 643-647.	0.9	8
11	Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunologic Research, 2018, 66, 642-648.	1.3	33
12	Disease-modifying therapies for multiple sclerosis. BMJ: British Medical Journal, 2018, 363, k4674.	2.4	76
13	Î±₄Î²₇ integrin inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2018, 28, 903-917.	2.4	18
14	Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers. Frontiers in Immunology, 2018, 9, 2602.	2.2	23
15	Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosisâ€"a randomized controlled trial. PeerJ, 2018, 6, e6037.	0.9	28
16	Central Nervous System Involvement in Common Variable Immunodeficiency: A Case of Acute Unilateral Optic Neuritis in a 26-Year-Old Italian Patient. Frontiers in Neurology, 2018, 9, 1031.	1.1	6
17	Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS. PLoS ONE, 2018, 13, e0208755.	1.1	5
18	Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS ONE, 2018, 13, e0209326.	1.1	13

#	Article	IF	Citations
19	The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731881318.	0.5	31
20	The Emerging Role of Neutrophil Granulocytes in Multiple Sclerosis. Journal of Clinical Medicine, 2018, 7, 511.	1.0	59
21	The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Journal of Clinical Medicine, 2018, 7, 494.	1.0	13
22	Ketogenic diets attenuate cyclooxygenase and lipoxygenase gene expression in multiple sclerosis. EBioMedicine, 2018, 36, 293-303.	2.7	46
23	The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis. Neurodegenerative Disease Management, 2018, 8, 323-335.	1.2	4
24	Role of the Fractalkine Receptor in CNS Autoimmune Inflammation: New Approach Utilizing a Mouse Model Expressing the Human CX3CR1I249/M280 Variant. Frontiers in Cellular Neuroscience, 2018, 12, 365.	1.8	44
25	Varicella-Zoster Virus in Cerebrospinal Fluid at Relapses of Multiple Sclerosis is Infective inÂVitro. Archives of Medical Research, 2018, 49, 350-355.	1.5	4
26	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	1.5	26
27	MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study. Frontiers in Neurology, 2018, 9, 718.	1.1	14
28	Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis. International Journal of Molecular Sciences, 2018, 19, 1639.	1.8	17
29	The Dual Immunoregulatory function of Nlrp12 in T Cell-Mediated Immune Response: Lessons from Experimental Autoimmune Encephalomyelitis. Cells, 2018, 7, 119.	1.8	23
30	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 497-498.	4.9	10
31	Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE, 2018, 13, e0197415.	1.1	46
32	Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials. Current Neurology and Neuroscience Reports, 2018, 18, 49.	2.0	13
33	Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. Biochemical Pharmacology, 2018, 157, 189-201.	2.0	33
34	Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. Clinical Chemistry and Laboratory Medicine, 2018, 57, 210-220.	1.4	24
35	T Follicular Helper Cells in Autoimmune Disorders. Frontiers in Immunology, 2018, 9, 1637.	2.2	164
36	Neurological Disease in Lupus: Toward a Personalized Medicine Approach. Frontiers in Immunology, 2018, 9, 1146.	2.2	36

#	Article	IF	Citations
37	Detection of Glycan Shedding in the Blood: New Class of Multiple Sclerosis Biomarkers?. Frontiers in Immunology, 2018, 9, 1254.	2.2	10
38	Reported Changes in Dietary Behavior Following a First Clinical Diagnosis of Central Nervous System Demyelination. Frontiers in Neurology, 2018, 9, 161.	1.1	21
39	Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. Frontiers in Molecular Neuroscience, 2018, 11, 164.	1.4	25
40	Emerging Cellular and Molecular Strategies for Enhancing Central Nervous System (CNS) Remyelination. Brain Sciences, 2018, 8, 111.	1.1	27
41	Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Annals of Neurology, 2018, 84, 315-328.	2.8	140
42	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. NeuroImage: Clinical, 2018, 20, 161-168.	1.4	22
43	Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e480.	3.1	19
44	Intestinal Microbiota Influences Non-intestinal Related Autoimmune Diseases. Frontiers in Microbiology, 2018, 9, 432.	1.5	137
45	Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Experimental and Molecular Pathology, 2018, 105, 175-180.	0.9	18
46	Microstructural correlates of 3D steadyâ€state inhomogeneous magnetization transfer (ihMT) in the human brain white matter assessed by myelin water imaging and diffusion tensor imaging. Magnetic Resonance in Medicine, 2018, 80, 2402-2414.	1.9	34
47	Le rÃ©entraÃ®nement des muscles respiratoires peut-il ajouter de la valeur au traitement du patient atteint de sclÃ©rose en plaquesÂ?. Kinesitherapie, 2018, 18, 20-21.	0.0	0
48	Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 246-250.	0.9	21
49	Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. CNS Drugs, 2018, 32, 939-949.	2.7	69
50	Exploring the role of physical activity and exercise for managing vascular comorbidities in people with multiple sclerosis: A scoping review. Multiple Sclerosis and Related Disorders, 2018, 26, 19-32.	0.9	24
51	Targeting Mitochondrial Metabolism in Neuroinflammation: Towards a Therapy for Progressive Multiple Sclerosis. Trends in Molecular Medicine, 2018, 24, 838-855.	3.5	59
52	Multiple sclerosis and mixed microbial infections. Direct identification of fungi and bacteria in nervous tissue. Neurobiology of Disease, 2018, 117, 42-61.	2.1	39
53	Dietary responses to a multiple sclerosis diagnosis: a qualitative study. European Journal of Clinical Nutrition, 2019, 73, 601-608.	1.3	22
54	Oligodendrocyte Bioenergetics in Health and Disease. Neuroscientist, 2019, 25, 334-343.	2.6	72

#	Article	IF	Citations
55	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. Clinical Autonomic Research, 2019, 29, 329-338.	1.4	6
56	Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurology, 2019, 76, 1474.	4.5	288
58	Stem Cell Therapy for Multiple Sclerosis: An Exciting Challenge or a Treatment Hope. Stem Cells in Clinical Applications, 2019, , 45-61.	0.4	1
59	Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews Drug Discovery, 2019, 18, 905-922.	21.5	265
60	General Principles of Immunotherapy in Neurological Diseases. Contemporary Clinical Neuroscience, 2019, , 387-421.	0.3	3
61	[11C]PIB PET imaging can detect white and grey matter demyelination in a non-human primate model of progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 108-115.	0.9	13
62	Roles for the adaptive immune system in Parkinsonâ€™s and Alzheimerâ€™s diseases. Current Opinion in Immunology, 2019, 59, 115-120.	2.4	38
63	Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature, 2019, 573, 75-82.	13.7	385
64	The anatomy and immunology of vasculature in the central nervous system. Science Immunology, 2019, 4, .	5.6	190
65	Immunoadsorption Techniques and Its Current Role in the Intensive Care Unit. , 2019, , .		2
66	Esclerosis mÃºltiple. Medicine, 2019, 12, 4587-4597.	0.0	3
67	Th1Th17_{CM} Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment. Mediators of Inflammation, 2019, 2019, 1-9.	1.4	7
68	An unmet clinical need: roads to remyelination in MS. Neurological Research and Practice, 2019, 1, 21.	1.0	19
69	Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses. Frontiers in Genetics, 2019, 10, 655.	1.1	17
70	Treatment with 6â€Gingerol Regulates Dendritic Cell Activity and Ameliorates the Severity of Experimental Autoimmune Encephalomyelitis. Molecular Nutrition and Food Research, 2019, 63, e1801356.	1.5	21
71	Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14791-14793.	3.3	0
72	The prevalence and utility of screening for urinary tract infection at the time of presumed multiple sclerosis relapse. Multiple Sclerosis and Related Disorders, 2019, 35, 61-66.	0.9	4
73	The Anti-Inflammatory Effect of Sulforaphane in Mice with Experimental Autoimmune Encephalomyelitis. Journal of Korean Medical Science, 2019, 34, e197.	1.1	21

#	Article	IF	Citations
74	Neuropathological features of â€œnonâ€•motorâ€•symptoms in multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2019, 10, 161-168.	0.5	3
75	Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology, 2019, 10, 1564.	2.2	117
76	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Multiple Sclerosis and Related Disorders, 2019, 35, 119-127.	0.9	30
77	Compared to an active control condition, in persons with multiple sclerosis two different types of exercise training improved sleep and depression, but not fatigue, paresthesia, and intolerance of uncertainty. Multiple Sclerosis and Related Disorders, 2019, 36, 101356.	0.9	37
78	Macrophage galactose-type lectin (MGL) is induced on M2 microglia and participates in the resolution phase of autoimmune neuroinflammation. Journal of Neuroinflammation, 2019, 16, 130.	3.1	23
79	Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients. Journal of Neuroimmunology, 2019, 337, 577065.	1.1	9
80	Sexual Dysfunction in Patients with Multiple Sclerosis from Argentina: What are the Differences Between Women and Men?. Sexuality and Disability, 2019, 37, 521-539.	0.4	11
81	Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis. Current Treatment Options in Neurology, 2019, 21, 53.	0.7	4
82	Progressive multiple sclerosis: latest therapeutic developments and future directions. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987832.	1.5	45
83	Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis Patients. Frontiers in Neuroscience, 2019, 13, 938.	1.4	24
84	Remyelination and ageing: Reversing the ravages of time. Multiple Sclerosis Journal, 2019, 25, 1835-1841.	1.4	63
85	An asymptomatic new lesion on MRI is a relapse and should be treated accordingly â€“ Commentary. Multiple Sclerosis Journal, 2019, 25, 1845-1847.	1.4	3
86	Patient education for fatigue in people with multiple sclerosis. The Cochrane Library, 0, , .	1.5	0
87	Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System. Frontiers in Neurology, 2019, 10, 1070.	1.1	17
89	Quetiapine has an additive effect to triiodothyronine in inducing differentiation of oligodendrocyte precursor cells through induction of cholesterol biosynthesis. PLoS ONE, 2019, 14, e0221747.	1.1	11
90	Altered Levels of Toll-Like Receptors in Circulating Extracellular Vesicles in Multiple Sclerosis. Cells, 2019, 8, 1058.	1.8	25
92	NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity. PLoS Biology, 2019, 17, e3000451.	2.6	21
93	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology, 2019, 293, 424-433.	3.6	36

#	Article	IF	Citations
94	Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain, 2019, 142, 3411-3427.	3.7	39
95	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells, 2019, 8, 1114.	1.8	40
96	Unraveling susceptibility to multiple sclerosis. Science, 2019, 365, 1383-1384.	6.0	7
98	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. NeuroImage: Clinical, 2019, 24, 102003.	1.4	93
99	A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 1046.	1.1	9
100	APTâ€weighted MRI: Techniques, current neuro applications, and challenging issues. Journal of Magnetic Resonance Imaging, 2019, 50, 347-364.	1.9	224
101	Blinded sample size reestimation in eventâ€driven clinical trials: Methods and an application in multiple sclerosis. Pharmaceutical Statistics, 2019, 18, 351-365.	0.7	13
102	Global, regional, and national burden of multiple sclerosis 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 269-285.	4.9	716
103	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. , 2019, 197, 122-152.		83
104	Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 642-651.	0.9	186
105	Highly active multiple sclerosis: An update. Multiple Sclerosis and Related Disorders, 2019, 30, 215-224.	0.9	66
106	A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4+ CD25high FOXP3+ Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contingent Upon Low-Efficiency T Cell Antigen Receptor Recognition. Frontiers in Immunology, 2019, 9, 3119.	2.2	7
107	Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Multiple Sclerosis and Related Disorders, 2019, 29, 86-93.	0.9	18
108	Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study. PLoS ONE, 2019, 14, e0211120.	1.1	17
109	Manganese Enhanced MRI for Use in Studying Neurodegenerative Diseases. Frontiers in Neural Circuits, 2019, 12, 114.	1.4	21
110	Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. Health Affairs, 2019, 38, 303-312.	2.5	18
112	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-Î±. Journal of Immunology, 2019, 203, 696-704.	0.4	6
113	Tear Off the Disease. , 2019, , 51-84.		0

#	Article	IF	Citations
114	Perception of stigma in patients with primary progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985271.	0.5	7
115	Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI. American Journal of Neuroradiology, 2019, 40, 1162-1169.	1.2	34
116	Tracking the evolution of CNS remyelinating lesion in mice with neutral red dye. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14290-14299.	3.3	22
117	The gut microbiota perspective for interventions in MS. Autoimmunity Reviews, 2019, 18, 814-824.	2.5	19
118	Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis. NeuroImage: Clinical, 2019, 23, 101879.	1.4	48
119	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€“ Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis, 2019, 34, 171-354.	0.7	1,263
120	A Higher Mediterranean Diet Score, Including Unprocessed Red Meat, Is Associated with Reduced Risk of Central Nervous System Demyelination in a Case-Control Study of Australian Adults. Journal of Nutrition, 2019, 149, 1385-1392.	1.3	36
121	Polypharmacy in patients with multiple sclerosis: a gender-specific analysis. Biology of Sex Differences, 2019, 10, 27.	1.8	18
122	Targeting the Chondroitin Sulfate Proteoglycans: Evaluating Fluorinated Glucosamines and Xylosides in Screens Pertinent to Multiple Sclerosis. ACS Central Science, 2019, 5, 1223-1234.	5.3	29
123	Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. Journal of Neurology, 2019, 266, 2208-2215.	1.8	2
124	Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis. Journal of Neuroimmunology, 2019, 334, 576974.	1.1	8
125	Access and unmet needs to multiple sclerosis care in a cohort of Argentinean patients. Multiple Sclerosis and Related Disorders, 2019, 33, 88-93.	0.9	23
126	Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances. Journal of Immunology Research, 2019, 2019, 1-10.	0.9	7
127	Neural mechanisms of perceptual decision-making and their link to neuropsychiatric symptoms in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 33, 139-145.	0.9	4
128	The potential of visual physiology: An instrument with a place in MS translation. Clinical Neurophysiology Practice, 2019, 4, 112-113.	0.6	1
129	Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature. Journal of Child Neurology, 2019, 34, 705-712.	0.7	42
130	Imaging the execution phase of neuroinflammatory disease models. Experimental Neurology, 2019, 320, 112968.	2.0	3
131	Assessing the risk of multiple sclerosis disease-modifying therapies. Expert Review of Neurotherapeutics, 2019, 19, 695-706.	1.4	8

#	Article	IF	Citations
132	Myelin in the Central Nervous System: Structure, Function, and Pathology. Physiological Reviews, 2019, 99, 1381-1431.	13.1	336
133	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmunity Reviews, 2019, 18, 665-672.	2.5	25
134	Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984709.	1.5	10
135	Neurodegenerative Interplay of Cardiovascular Autonomic Dysregulation and the Retina in Early Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 507.	1.1	2
136	Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. New England Journal of Medicine, 2019, 380, 2406-2417.	13.9	219
137	Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 6.	1.8	29
138	Epidemiology and treatment of multiple sclerosis in elderly populations. Nature Reviews Neurology, 2019, 15, 329-342.	4.9	185
139	Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. Glia, 2019, 67, 1510-1525.	2.5	28
140	Cognitive Profiles of Aging in Multiple Sclerosis. Frontiers in Aging Neuroscience, 2019, 11, 105.	1.7	43
141	Direct Lineage Reprogramming in the CNS. Advances in Experimental Medicine and Biology, 2019, 1212, 31-48.	0.8	5
142	Surgical management of patients with coexistent multiple sclerosis and cervical stenosis: A systematic review and meta-analysis. Journal of Clinical Neuroscience, 2019, 65, 77-82.	0.8	4
143	Gut Microbiota Regulation of T Cells During Inflammation and Autoimmunity. Annual Review of Immunology, 2019, 37, 599-624.	9.5	214
144	Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. Drug Safety, 2019, 42, 941-956.	1.4	12
145	Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors. Scientific Reports, 2019, 9, 3743.	1.6	19
146	Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 30, 284-290.	0.9	8
147	Autoimmunity in Parkinson's Disease: The Role of Î±-Synuclein-Specific T Cells. Frontiers in Immunology, 2019, 10, 303.	2.2	120
148	The role of vitamin D and P2X7R in multiple sclerosis. Journal of Neuroimmunology, 2019, 330, 159-169.	1.1	6
149	Magnetic resonance imaging diagnosis of demyelinating diseases: An update. Clinical and Experimental Neuroimmunology, 2019, 10, 32-48.	0.5	12

#	Article	IF	Citations
150	Dynamic gray matter volume changes in pediatric multiple sclerosis. Neurology, 2019, 92, e1709-e1723.	1.5	27
151	Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE. Cellular and Molecular Immunology, 2019, 16, 531-539.	4.8	85
152	Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 153.	1.1	13
153	Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis. Clinical Infectious Diseases, 2019, 69, 1757-1763.	2.9	14
154	Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 188.	1.1	52
155	Paediatric multiple sclerosis: a new era in diagnosis and treatment. Developmental Medicine and Child Neurology, 2019, 61, 1039-1049.	1.1	30
156	Pathological changes in mice with long term cuprizone administration. Neurochemistry International, 2019, 126, 229-238.	1.9	8
157	Gene variants of adhesion molecules predispose to MS: A case-control study. Neurology: Genetics, 2019, 5, e304.	0.9	14
158	Time to revisit oligodendrocytes in multiple sclerosis. Nature Medicine, 2019, 25, 364-366.	15.2	8
159	A surfaceâ€in gradient of thalamic damage evolves in pediatric multiple sclerosis. Annals of Neurology, 2019, 85, 340-351.	2.8	42
160	Barriers against a successful MS treatment: The importance of effectiveness beyond efficacy. Multiple Sclerosis and Related Disorders, 2019, 30, 129-135.	0.9	10
161	Oligodendrocyte-specific ATF4 inactivation does not influence the development of EAE. Journal of Neuroinflammation, 2019, 16, 23.	3.1	21
162	A genetic variant associated with multiple sclerosis inversely affects the expression of CD58 and microRNA-548ac from the same gene. PLoS Genetics, 2019, 15, e1007961.	1.5	17
163	Platelet Depletion is Effective in Ameliorating Anxiety-Like Behavior and Reducing the Pro-Inflammatory Environment in the Hippocampus in Murine Experimental Autoimmune Encephalomyelitis. Journal of Clinical Medicine, 2019, 8, 162.	1.0	23
164	The prevalence of MS in the United States. Neurology, 2019, 92, e1029-e1040.	1.5	765
165	A Survey of Assistive Technologies for Assessment and Rehabilitation of Motor Impairments in Multiple Sclerosis. Multimodal Technologies and Interaction, 2019, 3, 6.	1.7	14
166	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. Journal of Neurology, 2019, 266, 866-875.	1.8	36
167	Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. Journal of Clinical Investigation, 2019, 129, 4758-4768.	3.9	81

#	Article	IF	Citations
168	Epstein-Barr Virus in Multiple Sclerosis. , 2019, , .		1
170	Evaluating the relationship between psychometric intelligence and cognitive functions in paediatric multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989436.	0.5	7
171	Papel de la microbiota intestinal en el desarrollo de diferentes enfermedades neurolÃ³gicas. NeurologÃa, 2022, 37, 492-498.	0.3	21
172	Remyelination Pharmacotherapy Investigations Highlight Diverse Mechanisms Underlying Multiple Sclerosis Progression. ACS Pharmacology and Translational Science, 2019, 2, 372-386.	2.5	28
173	Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response. Neurological Research and Practice, 2019, 1, 40.	1.0	4
174	Treatment of the bone marrow stromal stem cell supernatant by nasal administrationâ€"a new approach to EAE therapy. Stem Cell Research and Therapy, 2019, 10, 325.	2.4	6
175	Synaptic Elimination in Neurological Disorders. Current Neuropharmacology, 2019, 17, 1071-1095.	1.4	63
176	Kappa opioid receptor and oligodendrocyte remyelination. Vitamins and Hormones, 2019, 111, 281-297.	0.7	5
177	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	5.8	87
178	Remyelination and the gutâ"brain axis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24922-24924.	3.3	6
179	Living with multiple sclerosis in South Africa: how is multiple sclerosis experienced in the workplace?. Disability and Rehabilitation, 2019, 43, 1-10.	0.9	3
180	Cranial Nerve Enhancement in Multiple Sclerosis Is Associated With Younger Age at Onset and More Severe Disease. Frontiers in Neurology, 2019, 10, 1085.	1.1	7
181	One, No One, and One Hundred Thousand: T Regulatory Cells' Multiple Identities in Neuroimmunity. Frontiers in Immunology, 2019, 10, 2947.	2.2	18
182	PARP-1 deregulation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989460.	0.5	10
183	Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis. BMC Neurology, 2019, 19, 339.	0.8	39
184	Molecular biomarkers in multiple sclerosis. Journal of Neuroinflammation, 2019, 16, 272.	3.1	158
185	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. Npj Digital Medicine, 2019, 2, 123.	5.7	35
186	Evoked potentials as a biomarker of remyelination. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 27074-27083.	3.3	37

#	Article	IF	Citations
187	What New Understanding of Progressive MS Reveals About Disease Progression. Neurology Today: an Official Publication of the American Academy of Neurology, 2019, 19, 25-26.	0.0	1
188	Increased Retention of Gadolinium in the Inflamed Brain After Repeated Administration of Gadopentetate Dimeglumine. Investigative Radiology, 2019, 54, 617-626.	3.5	30
189	X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 187-194.	0.9	8
190	Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain, 2019, 142, 133-145.	3.7	136
191	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 31-43.	1.4	44
192	Multiple Sclerosis: Destruction and Regeneration of Astrocytes in Acute Lesions. Journal of Neuropathology and Experimental Neurology, 2019, 78, 140-156.	0.9	28
193	Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1791-1799.	1.4	9
195	Management of dysphagia in multiple sclerosis: current best practice. Expert Review of Gastroenterology and Hepatology, 2019, 13, 47-54.	1.4	20
196	Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings. Clinical Imaging, 2019, 54, 53-56.	0.8	24
197	Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Multiple Sclerosis and Related Disorders, 2019, 27, 247-253.	0.9	10
198	A novel cognitive-behavioral stress management method for multiple sclerosis. A brief report of an observational study. Neurological Research, 2019, 41, 223-226.	0.6	10
199	Emotional processing in RRMS patients: Dissociation between behavioural and neurophysiological response. Multiple Sclerosis and Related Disorders, 2019, 27, 344-349.	0.9	16
200	The role of glialâ€“neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain. Immunotherapy, 2019, 11, 129-147.	1.0	17
201	Sephin1, which prolongs the integrated stress response, is a promising therapeutic for multiple sclerosis. Brain, 2019, 142, 344-361.	3.7	55
202	Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 165.	3.8	208
203	Incidence rate and sex ratio in multiple sclerosis in Lithuania. Brain and Behavior, 2019, 9, e01150.	1.0	14
204	Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF Î²-amyloid levels and brain volumes. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 280-287.	3.3	28
205	Increased CD74 binding and EAE treatment efficacy of a modified DRÎ±1 molecular construct. Metabolic Brain Disease, 2019, 34, 153-164.	1.4	10

#	Article	IF	Citations
206	Ultrahigh field imaging of myelin disease models: Toward specific markers of myelin integrity?. Journal of Comparative Neurology, 2019, 527, 2179-2189.	0.9	13
207	Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 514-521.	0.9	66
208	Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. Journal of Cellular Physiology, 2019, 234, 9943-9955.	2.0	29
209	Natural products: Potential therapeutic agents in multiple sclerosis. International Immunopharmacology, 2019, 67, 87-97.	1.7	24
210	A new frontier for amyloid PET imaging: multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 276-279.	3.3	7
211	miRâ€223 promotes regenerative myeloid cell phenotype and function in the demyelinated central nervous system. Glia, 2019, 67, 857-869.	2.5	42
212	Biotinidase deficiency should be considered in individuals thought to have multiple sclerosis and related disorders. Multiple Sclerosis and Related Disorders, 2019, 28, 26-30.	0.9	16
213	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	1.8	20
214	Headache in the course of multiple sclerosis: a prospective study. Journal of Neural Transmission, 2019, 126, 131-139.	1.4	11
215	Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. Inflammopharmacology, 2019, 27, 167-173.	1.9	16
216	Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of Neurology, 2020, 267, 308-316.	1.8	12
217	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. Multiple Sclerosis Journal, 2020, 26, 201-209.	1.4	24
218	The spectrum of spinal cord lesions in a primate model of multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 284-293.	1.4	8
219	Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 976-986.	1.4	28
220	Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study. Multiple Sclerosis Journal, 2020, 26, 1217-1226.	1.4	58
221	Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients. Multiple Sclerosis Journal, 2020, 26, 945-954.	1.4	11
222	Cerebrovascular reactivity and its correlation with age in patients with multiple sclerosis. Brain Imaging and Behavior, 2020, 14, 1889-1898.	1.1	9
223	Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsingâ€“remitting multiple sclerosis: a systematic review and network meta-analysis. Journal of Neurology, 2020, 267, 3489-3498.	1.8	82

#	Article	IF	Citations
224	Delirio de parasitosis en la esclerosis mÃºltiple: una expresiÃ³n enigmÃ¡tica de una enfermedad pleomÃ³rfica. NeurologÃa, 2020, 35, 445-448.	0.3	0
225	Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. Multiple Sclerosis Journal, 2020, 26, 1540-1549.	1.4	20
226	The â€œcentral vein signâ€•in patients with diagnostic â€œred flagsâ€•for multiple sclerosis: A prospective multicenter 3T study. Multiple Sclerosis Journal, 2020, 26, 421-432.	1.4	44
227	Treatment of multiple sclerosis with rituximab: A multicentric Italianâ€“Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	1.4	38
228	CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease. Journal of Investigative Medicine, 2020, 68, 321-330.	0.7	36
229	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	4.5	17
230	Urological Care for Patients with Progressive Neurological Conditions. , 2020, , .		0
231	Higher fish consumption and lower risk of central nervous system demyelination. European Journal of Clinical Nutrition, 2020, 74, 818-824.	1.3	15
232	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. Multiple Sclerosis Journal, 2020, 26, 1381-1391.	1.4	22
233	Quantitative brain relaxation atlases for personalized detection and characterization of brain pathology. Magnetic Resonance in Medicine, 2020, 83, 337-351.	1.9	19
235	T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients. Multiple Sclerosis Journal, 2020, 26, 1172-1186.	1.4	13
236	Yoga as an intervention to manage multiple sclerosis symptoms. Journal of Ayurveda and Integrative Medicine, 2020, 11, 114-117.	0.9	11
237	Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders. Metabolic Brain Disease, 2020, 35, 95-110.	1.4	6
238	Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?. Neurotherapeutics, 2020, 17, 218-234.	2.1	15
239	Physical activity interventions can improve emotion regulation and dimensions of empathy in persons with multiple sclerosis: An exploratory study. Multiple Sclerosis and Related Disorders, 2020, 37, 101380.	0.9	35
240	JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response. Clinical Immunology, 2020, 210, 108297.	1.4	3
241	Patterns of regional brain volume loss in multiple sclerosis: a cluster analysis. Journal of Neurology, 2020, 267, 395-405.	1.8	17
242	Do people with multiple sclerosis want to discuss their long-term prognosis? A nationwide study in Argentina. Multiple Sclerosis and Related Disorders, 2020, 37, 101445.	0.9	8

#	Article	IF	Citations
243	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101486.	0.9	11
244	Herpes viruses in optic neuritis: Similar to Bellâ€™s palsy. Clinical Neurology and Neurosurgery, 2020, 188, 105588.	0.6	4
245	Effects of inspiratory muscle training in advanced multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101492.	0.9	11
246	Exercise in multiple sclerosis and its models: Focus on the central nervous system outcomes. Journal of Neuroscience Research, 2020, 98, 509-523.	1.3	27
247	Diagnosis and management of central nervous system SjÃ¶gren's syndrome. , 2020, , 189-209.		0
248	Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease. Immunity, 2020, 52, 167-182.e7.	6.6	244
249	Low CSF Î²-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101899.	0.9	5
250	CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome. Journal of Translational Autoimmunity, 2020, 3, 100032.	2.0	32
251	Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4+ T cell CTLA-4 expression. Journal of Neuroimmunology, 2020, 338, 577105.	1.1	24
252	â€˜Prototypicalâ€™ proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. Expert Opinion on Therapeutic Targets, 2020, 24, 37-46.	1.5	16
253	The role of melatonin in Multiple Sclerosis. Neurological Sciences, 2020, 41, 769-781.	0.9	26
254	Crotoxin down-modulates pro-inflammatory cells and alleviates pain on the MOG35-55-induced experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Brain, Behavior, and Immunity, 2020, 84, 253-268.	2.0	21
255	Longitudinal evaluation of demyelinated lesions in a multiple sclerosis model using ultrashort echo time magnetization transfer (UTE-MT) imaging. NeuroImage, 2020, 208, 116415.	2.1	12
256	Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis. Journal of the Neurological Sciences, 2020, 409, 116619.	0.3	2
258	CSF Î²-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101462.	0.9	5
259	Exercise Effects on Multiple Sclerosis Quality of Life and Clinicalâ€“Motor Symptoms. Medicine and Science in Sports and Exercise, 2020, 52, 1007-1014.	0.2	44
260	The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A metaâ€analysis. British Journal of Clinical Pharmacology, 2020, 86, 637-645.	1.1	14
261	Multiscale entropy derived complexity index analysis demonstrates significant mediolateral sway in persons with multiple sclerosis compared to healthy controls. , 2020, 2020, 5176-5179.		2

#	Article	IF	Citations
262	Emerging Role of Extracellular Vesicles in the Pathophysiology of Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 7336.	1.8	39
263	Metabolic needs of brainâ€infiltrating leukocytes and microglia in multiple sclerosis. Journal of Neurochemistry, 2021, 158, 14-24.	2.1	8
264	Molecular patterns from a human gut-derived Lactobacillus strain suppress pathogenic infiltration of leukocytes into the central nervous system. Journal of Neuroinflammation, 2020, 17, 291.	3.1	5
265	Aminopiridines in the treatment of multiple sclerosis and other neurological disorders. Neurodegenerative Disease Management, 2020, 10, 409-423.	1.2	5
266	Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. Multiple Sclerosis and Related Disorders, 2020, 46, 102485.	0.9	26
267	Astrocyte Crosstalk in CNS Inflammation. Neuron, 2020, 108, 608-622.	3.8	423
268	Sex-Specific Effects of Microglia-Like Cell Engraftment during Experimental Autoimmune Encephalomyelitis. International Journal of Molecular Sciences, 2020, 21, 6824.	1.8	12
269	Microglia as therapeutic target in central nervous system disorders. Journal of Pharmacological Sciences, 2020, 144, 102-118.	1.1	19
270	Myelin detection in fluorescence microscopy images using machine learning. Journal of Neuroscience Methods, 2020, 346, 108946.	1.3	7
271	Re-Examining the Role of TNF in MS Pathogenesis and Therapy. Cells, 2020, 9, 2290.	1.8	52
272	Cervical spondylosis is a risk factor for localized spinal cord lesions in multiple sclerosis. Clinical Neurology and Neurosurgery, 2020, 199, 106311.	0.6	2
273	Evaluation of the potassium channel tracer [¹⁸F]3F4AP in rhesus macaques. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1721-1733.	2.4	27
274	MicroRNAs of Human Herpesvirus 6A and 6B in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Frontiers in Immunology, 2020, 11, 2142.	2.2	7
275	HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell, 2020, 183, 1264-1281.e20.	13.5	133
276	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation. Journal of Biological Chemistry, 2020, 295, 17413-17424.	1.6	29
277	Thyroid Hormone and Neural Stem Cells: Repair Potential Following Brain and Spinal Cord Injury. Frontiers in Neuroscience, 2020, 14, 875.	1.4	15
278	Effects of Retinal Transcription Regulation After GB20 Needling Treatment in Retina With Optic Neuritis. Frontiers in Integrative Neuroscience, 2020, 14, 568449.	1.0	6
279	Demographic and clinical characterization of multiple sclerosis in Mexico: The REMEMBer study. Multiple Sclerosis and Related Disorders, 2020, 46, 102575.	0.9	6

#	Article	IF	Citations
280	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. Neurobiology of Stress, 2020, 13, 100244.	1.9	10
281	Relapsing and progressive MS: the sex-specific perspective. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642095649.	1.5	15
282	Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Multiple Sclerosis and Related Disorders, 2020, 45, 102404.	0.9	14
283	Multiple sclerosis cortical and WM lesion segmentation at 3T MRI: a deep learning method based on FLAIR and MP2RAGE. NeuroImage: Clinical, 2020, 27, 102335.	1.4	54
284	The roles of iron and HFE genotype in neurological diseases. Molecular Aspects of Medicine, 2020, 75, 100867.	2.7	27
285	Delusional parasitosis in multiple sclerosis: an enigmatic manifestation of a multifaceted disease. NeurologÃa (English Edition), 2020, 35, 445-448.	0.2	0
286	Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases. Biomolecules, 2020, 10, 1044.	1.8	75
287	The Psychological Impact of COVID-19 Pandemic on People With Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 580507.	1.1	63
288	Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain, 2020, 143, 3574-3588.	3.7	110
290	Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients. Multiple Sclerosis Journal, 2021, 27, 1577-1584.	1.4	4
291	Curcumin, autoimmune and inflammatory diseases: going beyond conventional therapy â€“ a systematic review. Critical Reviews in Food Science and Nutrition, 2022, 62, 2140-2157.	5.4	16
292	Altered Functional Connectivity in White and Gray Matter in Patients With Multiple Sclerosis. Frontiers in Human Neuroscience, 2020, 14, 563048.	1.0	7
293	Peroxiredoxins in Neurodegenerative Diseases. Antioxidants, 2020, 9, 1203.	2.2	39
294	The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis. Diagnostics, 2020, 10, 1025.	1.3	30
295	Guanabenz modulates microglia and macrophages during demyelination. Scientific Reports, 2020, 10, 19333.	1.6	14
296	Induction of a higher-ordered architecture in glatiramer acetate improves its biological efficiency in an animal model of multiple sclerosis. Biomaterials Science, 2020, 8, 5271-5281.	2.6	3
297	Manganese-Enhanced MRI in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1569-1576.	1.2	3
298	Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China. Journal of Neuroimmunology, 2020, 347, 577351.	1.1	4

#	Article	IF	Citations
299	Connecting Immune Cell Infiltration to the Multitasking Microglia Response and TNF Receptor 2 Induction in the Multiple Sclerosis Brain. Frontiers in Cellular Neuroscience, 2020, 14, 190.	1.8	10
300	Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial. Frontiers in Human Neuroscience, 2020, 14, 255.	1.0	10
301	Improved Gait of Persons With Multiple Sclerosis After Rehabilitation: Effects on Lower Limb Muscle Synergies, Push-Off, and Toe-Clearance. Frontiers in Neurology, 2020, 11, 668.	1.1	9
302	Neuroimmunogastroenterology: At the Interface of Neuroimmunology and Gastroenterology. Frontiers in Neurology, 2020, 11, 787.	1.1	7
304	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. Frontiers in Neurology, 2020, 11, 756.	1.1	6
305	Parity and disability progression in relapsingâ€“remitting multiple sclerosis. Journal of Neurology, 2020, 267, 3753-3762.	1.8	11
307	Attitudes of patients with relapsing-remitting form of multiple sclerosis using disease-modifying drugs in Montenegro regarding COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2020, 45, 102380.	0.9	8
308	Regional differences in the association of cytomegalovirus seropositivity and multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 45, 102393.	0.9	13
309	Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse. Journal of Neuroimmunology, 2020, 347, 577355.	1.1	13
310	The Daam2â€“VHLâ€“Nedd4 axis governs developmental and regenerative oligodendrocyte differentiation. Genes and Development, 2020, 34, 1177-1189.	2.7	22
311	Cortical projection neurons as a therapeutic target in multiple sclerosis. Expert Opinion on Therapeutic Targets, 2020, 24, 1211-1224.	1.5	6
312	Matrine Inhibits CNS Autoimmunity Through an IFN-Î²-Dependent Mechanism. Frontiers in Immunology, 2020, 11, 569530.	2.2	17
313	Altered Coupling of Psychological Relaxation and Regional Volume of Brain Reward Areas in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 568850.	1.1	3
314	Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. Multiple Sclerosis and Related Disorders, 2020, 46, 102543.	0.9	13
315	Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide. Journal of Neuroscience, 2020, 40, 8587-8600.	1.7	13
316	Pro-inflammatory activation following demyelination is required for myelin clearance and oligodendrogenesis. Journal of Experimental Medicine, 2020, 217, .	4.2	87
317	An Absence of Epsteinâ€“Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines, 2020, 8, 487.	2.1	2
318	Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis. Frontiers in Endocrinology, 2020, 11, 574.	1.5	4

#	Article	IF	Citations
319	Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM). Neurological Sciences, 2020, 41, 3329-3335.	0.9	4
320	Immune Modulation of Platelet-Derived Mitochondria on Memory CD4+ T Cells in Humans. International Journal of Molecular Sciences, 2020, 21, 6295.	1.8	16
321	Brutonâ€™s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opinion on Emerging Drugs, 2020, 25, 377-381.	1.0	32
322	Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Multiple Sclerosis and Related Disorders, 2020, 46, 102469.	0.9	18
324	Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opinion on Drug Safety, 2020, 19, 1069-1094.	1.0	26
325	Beyond barrier functions: Roles of pericytes in homeostasis and regulation of neuroinflammation. Journal of Neuroscience Research, 2020, 98, 2390-2405.	1.3	24
326	Insight into the divergent role of TRAIL in nonâ€neoplastic neurological diseases. Journal of Cellular and Molecular Medicine, 2020, 24, 11070-11083.	1.6	5
327	Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Multiple Sclerosis Journal, 2021, 27, 1497-1505.	1.4	23
328	Serum ceramide levels are altered in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1506-1519.	1.4	20
329	Development and Validation of a Five-Gene Signature to Predict Relapse-Free Survival in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 579683.	1.1	6
330	A Metagenome-Wide Association Study of Gut Microbiome in Patients With Multiple Sclerosis Revealed Novel Disease Pathology. Frontiers in Cellular and Infection Microbiology, 2020, 10, 585973.	1.8	26
331	MCAM/CD146 Signaling via PLCÎ³1 Leads to Activation of Î²1-Integrins in Memory T-Cells Resulting in Increased Brain Infiltration. Frontiers in Immunology, 2020, 11, 599936.	2.2	9
332	Optical Coherence Tomography Angiography (OCTA) in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2020, 11, 604049.	1.1	32
333	Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity. International Journal of Molecular Sciences, 2020, 21, 9632.	1.8	5
334	Adherence to a healthy lifestyle and multiple sclerosis: a caseâ€“control study from the UK Biobank. Nutritional Neuroscience, 2020, , 1-9.	1.5	4
335	Among Persons With Multiple Sclerosis (MS), Objective Sleep, Psychological Functioning, and Higher Physical Activity Scores Remained Stable Over 2 Yearsâ€”Results From a Small Study Under Naturalistic Conditions. Frontiers in Psychiatry, 2020, 11, 586244.	1.3	7
336	Intrathecal Inflammation in Progressive Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 8217.	1.8	36
337	Inhibition of Human Neutrophil Functions In Vitro by Multiple Sclerosis Disease-Modifying Therapies. Journal of Clinical Medicine, 2020, 9, 3542.	1.0	3

#	Article	IF	Citations
338	Prognostic value of odor identification impairment in multiple sclerosis: 10-Years follow-up. Multiple Sclerosis and Related Disorders, 2020, 46, 102486.	0.9	6
339	Associations Between Findings From Myelin Water Imaging and Cognitive Performance Among Individuals With Multiple Sclerosis. JAMA Network Open, 2020, 3, e2014220.	2.8	18
340	Multiple Sklerose: Neuroinflammation und -degeneration Hand in Hand. Karger Kompass Autoimmun, 2020, 2, 147-150.	0.0	0
341	Dominant Antibiotic Consumption Patterns Might Be Associated With the Prevalence of Multiple Sclerosis in European Countries. In Vivo, 2020, 34, 3467-3472.	0.6	5
342	Effects of 12-week inspiratory muscle training with low resistance in patients with multiple sclerosis: A non-randomised, double-blind, controlled trial. Multiple Sclerosis and Related Disorders, 2020, 46, 102574.	0.9	7
343	Fibrin(ogen) in human disease: both friend and foe. Haematologica, 2020, 105, 284-296.	1.7	121
344	Acute vestibular syndrome and hearing loss mimicking labyrinthitis as initial presentation of multiple sclerosis. International Journal of Pediatric Otorhinolaryngology, 2020, 134, 110048.	0.4	5
345	Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina. Multiple Sclerosis and Related Disorders, 2020, 43, 102147.	0.9	7
346	Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 1326.	1.0	55
347	Motor learning promotes remyelination via new and surviving oligodendrocytes. Nature Neuroscience, 2020, 23, 819-831.	7.1	208
348	A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 771.	2.2	4
349	Doubleâ€blind , randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderateâ€toâ€severe relapses of multiple sclerosis. Journal of Clinical Apheresis, 2020, 35, 281-289.	0.7	7
350	Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent. Journal of Neurology, 2020, 267, 2619-2624.	1.8	20
351	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. Expert Opinion on Pharmacotherapy, 2020, 21, 1449-1454.	0.9	11
352	Experimental Models of Neuroimmunological Disorders: A Review. Frontiers in Neurology, 2020, 11, 389.	1.1	11
353	Incidence, prevalence and characteristics of MS in SÃ£o Miguel, an island in the Atlantic. Multiple Sclerosis and Related Disorders, 2020, 44, 102254.	0.9	2
354	What is the role of axonal ion channels in multiple sclerosis?. Neurology, 2020, 95, 120-123.	1.5	4
355	Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica, 2020, 105, 2056-2070.	1.7	70

#	Article	IF	Citations
356	Polymicrobial Infections and Neurodegenerative Diseases. Current Clinical Microbiology Reports, 2020, 7, 20-30.	1.8	5
357	Role of sphingolipid metabolism in neurodegeneration. Journal of Neurochemistry, 2021, 158, 25-35.	2.1	63
358	Aquatic exercising may improve sexual function in females with multiple sclerosis â€“ an exploratory study. Multiple Sclerosis and Related Disorders, 2020, 43, 102106.	0.9	17
359	Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. Trends in Molecular Medicine, 2020, 26, 898-912.	3.5	42
360	Spinal Cord Involvement in MS and Other Demyelinating Diseases. Biomedicines, 2020, 8, 130.	1.4	9
361	Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. Cells, 2020, 9, 1290.	1.8	23
362	The flavonoid agathisflavone modulates the microglial neuroinflammatory response and enhances remyelination. Pharmacological Research, 2020, 159, 104997.	3.1	14
363	Siponimod for multiple sclerosis. The Cochrane Library, 2020, , .	1.5	4
364	Semi-automatic detection of increased susceptibility in multiple sclerosis white matter lesions imaged with 1.5T MRI. Biomedical Signal Processing and Control, 2020, 61, 102043.	3.5	2
365	Commentary: The Multiple Sclerosis Controversy: Is It Escalation or Induction High Efficacy?. Neurotherapeutics, 2020, 17, 971-972.	2.1	2
366	Imaging Brain Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy. Trends in Neurosciences, 2020, 43, 343-354.	4.2	31
367	Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System. Brain Sciences, 2020, 10, 338.	1.1	32
368	Optical Coherence Tomography Angiography in Neurodegenerative Disorders. Journal of Clinical Medicine, 2020, 9, 1706.	1.0	46
369	Motor axonopathies in a mouse model of Duchenne muscular dystrophy. Scientific Reports, 2020, 10, 8967.	1.6	6
370	Transplantation of induced neural stem cells (iNSCs) into chronically demyelinated corpus callosum ameliorates motor deficits. Acta Neuropathologica Communications, 2020, 8, 84.	2.4	21
371	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	1.8	19
372	Reactive Balance Adaptability and Retention in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis. Neurorehabilitation and Neural Repair, 2020, 34, 675-685.	1.4	13
373	CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	23

#	Article	IF	Citations
374	iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu. PLoS ONE, 2020, 15, e0233980.	1.1	28
375	A Digital Patient Portal for Patients With Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 400.	1.1	22
376	Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. The Cochrane Library, 0, , .	1.5	3
377	Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes. Annals of Clinical and Translational Neurology, 2020, 7, 406-419.	1.7	59
378	Astrocyte and Oligodendrocyte Cross-Talk in the Central Nervous System. Cells, 2020, 9, 600.	1.8	100
379	Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. Trends in Immunology, 2020, 41, 341-354.	2.9	14
380	Altered secretory and neuroprotective function of the choroid plexus in progressive multiple sclerosis. Acta Neuropathologica Communications, 2020, 8, 35.	2.4	38
381	Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 208-219.	1.4	12
382	Epigenetic Mechanisms of the Pathogenesis of Multiple Sclerosis. Human Physiology, 2020, 46, 104-112.	0.1	3
383	The therapeutic potential of bilobalide on experimental autoimmune encephalomyelitis (EAE) mice. Metabolic Brain Disease, 2020, 35, 793-807.	1.4	5
384	Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis. International Journal of Medical Sciences, 2020, 17, 751-761.	1.1	21
385	Role of diet in regulating the gut microbiota and multiple sclerosis. Clinical Immunology, 2022, 235, 108379.	1.4	19
386	Electrophile Signaling and Emerging Immuno- and Neuro-modulatory Electrophilic Pharmaceuticals. Frontiers in Aging Neuroscience, 2020, 12, 1.	1.7	84
387	Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) â€“ preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. BMC Neurology, 2020, 20, 75.	0.8	10
388	Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis. Frontiers in Cellular Neuroscience, 2020, 14, 169.	1.8	35
389	The Gutâ€“CNS Axis in Multiple Sclerosis. Trends in Neurosciences, 2020, 43, 622-634.	4.2	64
390	Growth differentiation factor 15 is increased in stable MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	12
391	Factors associated with relapses in relapsing-remitting multiple sclerosis. Medicine (United States), 2020, 99, e20885.	0.4	14

#	Article	IF	Citations
392	â€˜It struck at the heart of who I thought I wasâ€™: A metaâ€synthesis of the qualitative literature examining the experiences of people with multiple sclerosis. Health Expectations, 2020, 23, 1007-1027.	1.1	34
393	Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance. Journal of Neurology, 2020, 267, 3287-3291.	1.8	2
394	The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. Patient, 2020, 13, 583-597.	1.1	5
395	Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Scientific Reports, 2020, 10, 10923.	1.6	66
396	Multiple sclerosis with intractable vomiting and atypical area postrema lesion. Multiple Sclerosis and Related Disorders, 2020, 45, 102348.	0.9	6
397	Tissue Transglutaminase contributes to myelin phagocytosis in interleukin-4-treated human monocyte-derived macrophages. Cytokine, 2020, 128, 155024.	1.4	8
398	Editorial: Multiple Sclerosis â€“ From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on Patients. Frontiers in Immunology, 2020, 11, 137.	2.2	4
399	Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis. Journal of Neuroimmunology, 2020, 342, 577188.	1.1	14
400	Identification of a predominant cognitive phenotype in patients with multiple sclerosis. European Journal of Neurology, 2020, 27, 1083-1088.	1.7	9
401	Viral infections and multiple sclerosis. Drug Discovery Today: Disease Models, 2020, 32, 27-33.	1.2	44
402	Natural killer cells in multiple sclerosis: A review. Immunology Letters, 2020, 222, 1-11.	1.1	34
403	Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis. NeuroImage, 2020, 213, 116690.	2.1	11
404	Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. Expert Opinion on Drug Safety, 2020, 19, 139-145.	1.0	32
405	Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 192-217.	2.0	69
406	Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. Journal of the Neurological Sciences, 2020, 411, 116668.	0.3	26
407	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Review of Neurotherapeutics, 2020, 20, 771-782.	1.4	6
408	Physical activity and peak oxygen consumption are associated with walking in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 40, 101941.	0.9	5
409	Metabolomics in multiple sclerosis disease course and progression. Multiple Sclerosis Journal, 2020, 26, 591-598.	1.4	36

#	Article	IF	Citations
410	That Wasnâ€™t a Complementâ€”Too Much C3 in Demyelinating Disease. Immunity, 2020, 52, 11-13.	6.6	7
411	Neuroinflammation in CNS diseases: Molecular mechanisms and the therapeutic potential of plant derived bioactive molecules. PharmaNutrition, 2020, 11, 100176.	0.8	26
412	Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. Journal of Neuroimmunology, 2020, 341, 577170.	1.1	10
413	Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis. Journal of Nuclear Medicine, 2020, 61, 1043-1049.	2.8	24
414	A mouse model of MSU-induced acute inflammation in vivo suggests imiquimod-dependent targeting of Il-1Î² as relevant therapy for gout patients. Theranostics, 2020, 10, 2158-2171.	4.6	28
415	Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability. NeuroImage: Clinical, 2020, 25, 102177.	1.4	24
416	Inflammation of the choroid plexus in progressive multiple sclerosis: accumulation of granulocytes and T cells. Acta Neuropathologica Communications, 2020, 8, 9.	2.4	45
417	Dynamic Balance of Microglia and Astrocytes Involved in the Remyelinating Effect of Ginkgolide B. Frontiers in Cellular Neuroscience, 2020, 13, 572.	1.8	21
418	Vitamin D and other environmental risk factors in Colombian patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 41, 101983.	0.9	1
419	Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 594.	2.2	33
420	Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response. Frontiers in Immunology, 2020, 11, 615.	2.2	143
421	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurological Sciences, 2020, 41, 3175-3183.	0.9	16
422	Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis. PLoS ONE, 2020, 15, e0226050.	1.1	14
423	Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study. International Journal of Risk and Safety in Medicine, 2020, 31, 259-265.	0.3	6
424	CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders. Journal of Immunology, 2020, 204, 3-11.	0.4	48
425	Diagnostic and therapeutic issues of inflammatory diseases of the elderly. Revue Neurologique, 2020, 176, 739-749.	0.6	3
426	Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase. Biochemical Pharmacology, 2020, 177, 114000.	2.0	12
427	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e644.	3.1	1

#	Article	IF	Citations
428	Adherence to self-administering interferon-Î²1a using RebiSmartÂ® device in Mexican patients with relapsing multiple sclerosis. PLoS ONE, 2020, 15, e0230959.	1.1	8
429	Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy. Annals of Neurology, 2020, 87, 885-896.	2.8	56
430	Reliability of gait and dual-task measures in multiple sclerosis. Gait and Posture, 2020, 78, 19-25.	0.6	8
431	New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. Expert Opinion on Investigational Drugs, 2020, 29, 443-459.	1.9	31
432	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 821-834.	1.4	17
433	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain, 2020, 143, 1127-1142.	3.7	29
434	Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 843-854.	1.4	21
435	Deubiquitinating enzymes (DUBs): DoUBle-edged swords in CNS autoimmunity. Journal of Neuroinflammation, 2020, 17, 102.	3.1	21
436	A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematology, Transfusion and Cell Therapy, 2021, 43, 65-86.	0.1	15
437	Frailty in ageing persons with multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 613-620.	1.4	22
438	Synaptic and complement markers in extracellular vesicles in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 509-518.	1.4	38
439	Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis. Clinical Reviews in Allergy and Immunology, 2021, 60, 147-163.	2.9	18
440	Impairing committed cholesterol biosynthesis in white matter astrocytes, but not grey matter astrocytes, enhances in vitro myelination. Journal of Neurochemistry, 2021, 156, 624-641.	2.1	14
441	Promoting remyelination in multiple sclerosis. Journal of Neurology, 2021, 268, 30-44.	1.8	79
442	A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102619.	0.9	14
443	Acute motor deficit and subsequent remyelinationâ€associated recovery following internal capsule demyelination in mice. Journal of Neurochemistry, 2021, 156, 917-928.	2.1	14
444	Fast and highâ€resolution myelin water imaging: Accelerating multiâ€echo GRASE with CAIPIRINHA. Magnetic Resonance in Medicine, 2021, 85, 209-222.	1.9	16
445	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	1.7	6

#	Article	IF	Citations
446	Developmental venous anomalies in patients with multiple sclerosis: is that a coincidence or an ancillary finding?. Neurological Sciences, 2021, 42, 2453-2460.	0.9	4
447	Coping strategies used by patients with relapsing multiple sclerosis from Argentina: correlation with quality of life and clinical features. Neurological Research, 2021, 43, 126-132.	0.6	7
448	Altered astrocytic function in experimental neuroinflammation and multiple sclerosis. Glia, 2021, 69, 1341-1368.	2.5	24
449	Neuronal and Endothelial Transglutaminase-2 Expression during Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Neuroscience, 2021, 461, 140-154.	1.1	5
450	Retinal asymmetry in multiple sclerosis. Brain, 2021, 144, 224-235.	3.7	20
451	Positive association of herpes simplex virus-IgG with multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 47, 102633.	0.9	14
452	Fatigue and fluctuations in physical and psychological wellbeing in people with multiple sclerosis: A longitudinal study. Multiple Sclerosis and Related Disorders, 2021, 47, 102602.	0.9	17
453	The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review. Journal of the Neurological Sciences, 2021, 420, 117229.	0.3	23
454	Prevalence and incidence of multiple sclerosis in Ardabil, Northwest of Iran. Multiple Sclerosis and Related Disorders, 2021, 47, 102605.	0.9	6
455	Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. Neurology and Therapy, 2021, 10, 183-196.	1.4	12
456	Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. British Journal of Clinical Pharmacology, 2021, 87, 2511-2520.	1.1	39
457	First line treatment failure: Predictive factors in a cohort of 863 Relapsing Remitting MS patients. Multiple Sclerosis and Related Disorders, 2021, 48, 102686.	0.9	6
458	High serum neurofilament associates with diffuse white matter damage in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	25
459	Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nature Neuroscience, 2021, 24, 47-60.	7.1	134
460	The sequence of structural, functional and cognitive changes in multiple sclerosis. NeuroImage: Clinical, 2021, 29, 102550.	1.4	21
461	Biosensor vital sign detects multiple sclerosis progression. Annals of Clinical and Translational Neurology, 2021, 8, 4-14.	1.7	6
462	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Review of Neurotherapeutics, 2021, 21, 131-140.	1.4	11
463	Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis. Brain, 2021, 144, 162-185.	3.7	11

#	Article	IF	Citations
464	Multiple sclerosis identification in brain<scp>MRI</scp>images using wavelet convolutional neural networks. International Journal of Imaging Systems and Technology, 2021, 31, 778-785.	2.7	16
465	Sex differences in EAE reveal common and distinct cellular and molecular components. Cellular Immunology, 2021, 359, 104242.	1.4	30
466	Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population. Journal of Neurology, 2021, 268, 506-515.	1.8	7
467	Probing myelin content of the human brain with MRI: A review. Magnetic Resonance in Medicine, 2021, 85, 627-652.	1.9	42
468	Assessment of Racial/Ethnic Disparities in Volumetric MRI Correlates of Clinical Disability in Multiple Sclerosis: A Preliminary Study. Journal of Neuroimaging, 2021, 31, 115-123.	1.0	14
469	Ultrahigh-resolution MRI Reveals Extensive Cortical Demyelination in a Nonhuman Primate Model of Multiple Sclerosis. Cerebral Cortex, 2021, 31, 439-447.	1.6	7
470	Which behavioural and exercise interventions targeting fatigue show the most promise in multiple sclerosis? A systematic review with narrative synthesis and meta-analysis. Behaviour Research and Therapy, 2021, 137, 103464.	1.6	43
471	Tryptamine Attenuates Experimental Multiple Sclerosis Through Activation of Aryl Hydrocarbon Receptor. Frontiers in Pharmacology, 2020, 11, 619265.	1.6	21
474	Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort. Multiple Sclerosis Journal, 2021, 27, 1914-1923.	1.4	17
475	Can white matter lesion burden predict involvement of normal appearing thalami in multiple sclerosis? Study using 3D FLAIR and DTI. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.3	0
476	Current Developments in Diagnostic Biosensor Technology: Relevance to Therapeutic Intervention of Infectious and Inflammatory Diseases of Human. Studies in Systems, Decision and Control, 2021, , 1-36.	0.8	3
477	Risk factors for relapse in relapsing remitting multiple sclerosis. British Journal of Neuroscience Nursing, 2021, 17, S34-S36.	0.1	0
478	Exploring polypharmacy phenomenon in newly diagnosed relapsingâ€“remitting multiple sclerosis: a cohort ambispective single-centre study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232098312.	1.1	16
479	Antigen Presentation by B Cells in Multiple Sclerosis. New England Journal of Medicine, 2021, 384, 378-381.	13.9	18
481	Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 600428.	2.2	25
482	Neuroimmune connections between corticotropin-releasing hormone and mast cells: novel strategies for the treatment of neurodegenerative diseases. Neural Regeneration Research, 2021, 16, 2184.	1.6	13
483	Research Progress of Multiple Sclerosis Associated Oculomotor Dysfunction. Advances in Clinical Medicine, 2021, 11, 1959-1962.	0.0	0
484	Urinary incontinence and impaired physical function are associated with expiratory muscle weakness in patients with multiple sclerosis. Disability and Rehabilitation, 2022, 44, 3531-3539.	0.9	3

#	Article	IF	Citations
486	Reduced Fragmentation of IGFBP-2 and IGFBP-3 as a Potential Mechanism for Decreased Ratio of IGF-II to IGFBPs in Cerebrospinal Fluid in Response to Repeated Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis. Frontiers in Endocrinology, 2020, 11, 565557.	1.5	2
487	Concepts of Immune Therapy and Disease Management. , 2021, , 59-71.		0
488	Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	21
489	Phagocyte-mediated synapse removal in cortical neuroinflammation is promoted by local calcium accumulation. Nature Neuroscience, 2021, 24, 355-367.	7.1	49
490	Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review. Journal of NeuroImmune Pharmacology, 2021, 16, 251-269.	2.1	27
491	cGAS- Stimulator of Interferon Genes Signaling in Central Nervous System Disorders. , 2021, 12, 1658.		12
492	Introduction to Neuroimmunology: What the Cerebrospinal Fluid Teaches Us About Diseases of the Central Nervous System. , 2021, , 3-13.		0
493	Immune Dysfunction and Catatonia. , 2021, , 309-319.		0
494	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 573-595.	1.4	38
495	Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 256-262.	0.5	3
496	A randomised controlled trial to test the feasibility of online mindfulness programs for people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 48, 102728.	0.9	14
497	Multiple Sclerosis Phenotypes. , 2021, , 37-44.		2
499	Clinical Features of Multiple Sclerosis. , 2021, , 21-36.		0
500	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919.	2.1	9
501	Peroxisome Proliferator-Activated Receptor-Î´ Deficiency in Microglia Results in Exacerbated Axonal Injury and Tissue Loss in Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2021, 12, 570425.	2.2	10
502	Diagnostic Evaluation. , 2021, , 45-58.		0
503	Radiochemical Synthesis and Evaluation in Non-Human Primates of 3-[¹¹C]methoxy-4-aminopyridine: A Novel PET Tracer for Imaging Potassium Channels in the CNS. ACS Chemical Neuroscience, 2021, 12, 756-765.	1.7	8
504	Epigallocatechin Gallate in Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	12

#	Article	IF	Citations
505	Diet-dependent regulation of TGFÎ² impairs reparative innate immune responses after demyelination. Nature Metabolism, 2021, 3, 211-227.	5.1	41
506	Leveraging electronic health records data to predict multiple sclerosis disease activity. Annals of Clinical and Translational Neurology, 2021, 8, 800-810.	1.7	19
507	Immune repertoire: Revealing the â€œreal-timeâ€•adaptive immune response in autoimmune diseases. Autoimmunity, 2021, 54, 61-75.	1.2	3
509	Pediatric Multiple Sclerosis. , 2021, , 193-210.		0
510	Incorporating patientsâ€™ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 183-195.	0.7	2
511	Neutrophilâ€toâ€lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review. Acta Neurologica Scandinavica, 2021, 143, 577-586.	1.0	27
512	Motor Sequence Learning across Multiple Sessions Is Not Facilitated by Targeting Consolidation with Posttraining tDCS in Patients with Progressive Multiple Sclerosis. Neural Plasticity, 2021, 2021, 1-11.	1.0	3
513	Factors influencing patientsâ€™ willingness-to-pay for disease-modifying therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 48, 102720.	0.9	3
514	Quantitative evaluation of callosal abnormalities in relapsing-remitting multiple sclerosis using diffusion tensor imaging: A systemic review and meta-analysis. Clinical Neurology and Neurosurgery, 2021, 201, 106442.	0.6	5
515	Viral mouse models used to study multiple sclerosis: past and present. Archives of Virology, 2021, 166, 1015-1033.	0.9	13
516	Cuprizone-Induced Neurotoxicity in Human Neural Cell Lines Is Mediated by a Reversible Mitochondrial Dysfunction: Relevance for Demyelination Models. Brain Sciences, 2021, 11, 272.	1.1	9
517	Galangin ameliorates experimental autoimmune encephalomyelitis in mice via modulation of cellular immunity. Journal of Immunotoxicology, 2021, 18, 50-60.	0.9	3
519	Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis. Neurology, 2021, 96, e2058-e2069.	1.5	35
520	Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation. Journal of Experimental Medicine, 2021, 218, .	4.2	20
521	Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment. ELife, 2021, 10, .	2.8	17
522	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. European Journal of Neurology, 2022, 29, 1075-1081.	1.7	16
523	Multiple sclerosis risk gene Mertk is required for microglial activation and subsequent remyelination. Cell Reports, 2021, 34, 108835.	2.9	61
524	Involvement of cytotoxic Eomes-expressing CD4 ⁺ T cells in secondary progressive multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	47

#	Article	IF	Citations
525	Strength Exercise Confers Protection in Central Nervous System Autoimmunity by Altering the Gut Microbiota. Frontiers in Immunology, 2021, 12, 628629.	2.2	19
526	Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience. Neurological Sciences, 2021, 42, 5037-5043.	0.9	2
527	CENTRAL MYELIN AND DEMYELINATION. , 2021, , 77-79.		0
528	Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients. Frontiers in Neurology, 2021, 12, 632917.	1.1	3
529	Modulation of the HMGB1/TLR4/NF-Î²B signaling pathway in the CNS by matrine in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2021, 352, 577480.	1.1	27
530	Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials. Frontiers in Immunology, 2021, 12, 611711.	2.2	13
531	Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigueâ€"Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers. Biomolecules, 2021, 11, 393.	1.8	6
532	Dedicated 3D-T2-STIR-ZOOMit Imaging Improves Demyelinating Lesion Detection in the Anterior Visual Pathways of Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2021, 42, 1061-1068.	1.2	2
533	Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. Brain, 2021, 144, 1684-1696.	3.7	61
534	Gluten intolerance antibodies in multiple sclerosis and clinically isolated syndrome : Coexistent or coincidental?. Clinical and Experimental Neuroimmunology, 2021, 12, 116-121.	0.5	1
535	Antigen-Specific Immune Tolerance in Multiple Sclerosisâ€"Promising Approaches and How to Bring Them to Patients. Frontiers in Immunology, 2021, 12, 640935.	2.2	20
536	How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study. Quality of Life Research, 2021, 30, 2081-2096.	1.5	5
537	Diversity and Function of Glial Cell Types in Multiple Sclerosis. Trends in Immunology, 2021, 42, 228-247.	2.9	41
538	miR-124: A Promising Therapeutic Target for Central Nervous System Injuries and Diseases. Cellular and Molecular Neurobiology, 2022, 42, 2031-2053.	1.7	13
539	Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. Clinical Pharmacokinetics, 2021, 60, 1239-1250.	1.6	5
540	Macrophages and Autoantibodies in Demyelinating Diseases. Cells, 2021, 10, 844.	1.8	26
541	Altered distributions in circulating follicular helper and follicular regulatory T cells accountable for imbalanced cytokine production in multiple sclerosis. Clinical and Experimental Immunology, 2021, 205, 75-88.	1.1	8
542	Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	4

#	Article	IF	Citations
544	Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using ¹⁸F-FAraG PET and MRI. Journal of Nuclear Medicine, 2022, 63, 140-146.	2.8	14
545	A Soluble Epoxide Hydrolase Inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis. International Journal of Molecular Sciences, 2021, 22, 4650.	1.8	10
546	Thermal Liquid Biopsy (TLB) of Blood Plasma as a Potential Tool to Help in the Early Diagnosis of Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 295.	1.1	6
547	The Evolution of Neurofilament Light Chain in Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 642384.	1.4	62
548	p57kip2 nuclear export as a marker of oligodendrocytes differentiation: Towards an innovative phenotyping screening for the identification of myelin repair drugs. EBioMedicine, 2021, 66, 103298.	2.7	1
549	FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models. Cells, 2021, 10, 884.	1.8	27
550	Circulating Interleukins and Risk of Multiple Sclerosis: A Mendelian Randomization Study. Frontiers in Immunology, 2021, 12, 647588.	2.2	19
551	Navigating dietary advice for multiple sclerosis. Health Expectations, 2021, 24, 853-862.	1.1	9
552	Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile. Neurological Sciences, 2021, 42, 5241-5247.	0.9	3
553	Onychomycosis in patients with multiple sclerosis: prevalence, clinical description, mycological, and dermoscopic study in a Mexican population. International Journal of Dermatology, 2021, 60, 1102-1108.	0.5	0
554	Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptomsâ€"A Narrative Review. Neurology and Therapy, 2021, 10, 75-98.	1.4	50
555	Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study. Frontiers in Neurology, 2021, 12, 615790.	1.1	7
556	Periodized versus classic exercise therapy in Multiple Sclerosis: a randomized controlled trial. Multiple Sclerosis and Related Disorders, 2021, 49, 102782.	0.9	6
557	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nature Communications, 2021, 12, 2078.	5.8	112
558	Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation. Cell Chemical Biology, 2021, 28, 537-545.e4.	2.5	7
559	Therapeutic Potential and Immunomodulatory Role of Coenzyme Q10 and Its Analogues in Systemic Autoimmune Diseases. Antioxidants, 2021, 10, 600.	2.2	17
560	Microglia and Central Nervous Systemâ€"Associated Macrophagesâ€"From Origin to Disease Modulation. Annual Review of Immunology, 2021, 39, 251-277.	9.5	228
561	The Prognostic Value of White-Matter Selective Double Inversion Recovery MRI Sequence in Multiple Sclerosis: An Exploratory Study. Diagnostics, 2021, 11, 686.	1.3	1

#	Article	IF	Citations
562	Illumination of Molecular Pathways in Multiple Sclerosis Lesions and the Immune Mechanism of Matrine Treatment in EAE, a Mouse Model of MS. Frontiers in Immunology, 2021, 12, 640778.	2.2	10
563	Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates. Neurology and Therapy, 2021, 10, 435-454.	1.4	2
564	Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis. Neurology, 2021, 96, e2525-e2533.	1.5	9
565	Multiple sclerosis lesion segmentation from brain MRI using U-Net based on wavelet pooling. International Journal of Computer Assisted Radiology and Surgery, 2021, 16, 1459-1467.	1.7	11
566	Astrocytes in Multiple Sclerosisâ€"Essential Constituents with Diverse Multifaceted Functions. International Journal of Molecular Sciences, 2021, 22, 5904.	1.8	24
567	Digital Twins for Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 669811.	2.2	108
568	Role of the gut microbiota in the development of various neurological diseases. NeurologÃa (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	8
569	Patients and neurologists have different perceptions of multiple sclerosis symptoms, care and challenges. Multiple Sclerosis and Related Disorders, 2021, 50, 102806.	0.9	12
570	Evaluation of treatment effects of semantic feature analysis on mild anomia in multiple sclerosis. Aphasiology, 2022, 36, 706-731.	1.4	2
571	Ocrelizumab as a breakthrogh in multiple sclerosis treatment. Journal of Education, Health and Sport, 2021, 11, 50.	0.0	0
572	Synergistic neuroprotective effects of Fingolimod and mesenchymal stem cells (MSC) in experimental autoimmune encephalomyelitis. Immunology Letters, 2021, 233, 11-19.	1.1	1
573	Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 639315.	1.1	19
574	Targeting the brain lesions using peptides: A review focused on the possibility of targeted drug delivery to multiple sclerosis lesions. Pharmacological Research, 2021, 167, 105441.	3.1	7
575	Innate Lymphoid Cells in Tissue Homeostasis and Disease Pathogenesis. Molecules and Cells, 2021, 44, 301-309.	1.0	15
576	Factors that influence quality of life in patients with multiple sclerosis in Saudi Arabia. Disability and Rehabilitation, 2022, 44, 4775-4783.	0.9	4
577	Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis. Stem Cell Research, 2021, 53, 102319.	0.3	13
578	Caspase-11 Noncanonical Inflammasome: A Novel Key Player in Murine Models of Neuroinflammation and Multiple Sclerosis. NeuroImmunoModulation, 2021, 28, 195-203.	0.9	15
580	Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 50, 102816.	0.9	39

#	Article	IF	Citations
581	Current review and next steps for artificial intelligence in multiple sclerosis risk research. Computers in Biology and Medicine, 2021, 132, 104337.	3.9	10
582	Exercise leads to metabolic changes associated with improved strength and fatigue in people with MS. Annals of Clinical and Translational Neurology, 2021, 8, 1308-1317.	1.7	6
583	Fingolimod in pediatric-onset multiple sclerosis. Neurological Sciences, 2021, 42, 1-4.	0.9	2
585	Advanced Analysis of Diffusion Tensor Imaging Along With Machine Learning Provides New Sensitive Measures of Tissue Pathology and Intra-Lesion Activity in Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 634063.	1.4	7
586	Fasudil enhances the phagocytosis of myelin debris and the expression of neurotrophic factors in cuprizone-induced demyelinating mice. Neuroscience Letters, 2021, 753, 135880.	1.0	6
587	The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems?. Brain, Behavior, and Immunity, 2021, 94, 381-391.	2.0	22
588	Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. Current Opinion in Neurology, 2021, 34, 598-603.	1.8	16
589	Analysis of inflammasomes and CYP27B1 genes in cuprizone demyelinated C57BL/6 mice and evaluation of Th1 and Th2 patterns after oral administration of Lactobacillus casei strain T2 (IBRC-M10783). Microbial Pathogenesis, 2021, 155, 104931.	1.3	2
590	Metabolic Control of Smoldering Neuroinflammation. Frontiers in Immunology, 2021, 12, 705920.	2.2	19
591	Update on brain MRI for the diagnosis and follow-up of MS patients. Presse Medicale, 2021, 50, 104067.	0.8	5
592	A Digital Twins Machine Learning Model for Forecasting Disease Progression in Stroke Patients. Applied Sciences (Switzerland), 2021, 11, 5576.	1.3	14
593	The potential of serum neurofilament as biomarker for multiple sclerosis. Brain, 2021, 144, 2954-2963.	3.7	98
594	Use of geographical information systems in multiple sclerosis research: A systematic scoping review. Multiple Sclerosis and Related Disorders, 2021, 51, 102909.	0.9	9
595	Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 857-876.	1.9	9
596	Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating TÂcell responses and modifies the spinal cord lipidome. Cell Reports, 2021, 35, 109201.	2.9	30
597	Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurology, The, 2021, 20, 470-483.	4.9	96
598	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 701752.	2.2	17
599	Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence. Expert Review of Neurotherapeutics, 2021, 21, 715-725.	1.4	12

#	Article	IF	Citations
600	Rate, burden, and treatment of sexual dysfunction in multiple sclerosis: The case for exercise training as a new treatment approach. Multiple Sclerosis and Related Disorders, 2021, 51, 102878.	0.9	11
601	Dapsone, More than an Effective Neuro and Cytoprotective Drug. Current Neuropharmacology, 2022, 20, 194-210.	1.4	8
602	State-of-the-Art Review: Demyelinating Diseases in Indonesia. Multiple Sclerosis International, 2021, 2021, 1-13.	0.4	1
603	Diagnostic Dilemma: An Atypical Case of Astrocytoma in a Patient with Relapsingâ€“Remitting Multiple Sclerosis. Neurology International, 2021, 13, 240-251.	1.3	1
604	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology, 2021, 97, e543-e553.	1.5	54
605	The functional reach test in people with multiple sclerosis: a reliability and validity study. Physiotherapy Theory and Practice, 2022, 38, 2905-2919.	0.6	6
606	Extracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases. Molecular Biomedicine, 2021, 2, 18.	1.7	17
607	Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes. PLoS Pathogens, 2021, 17, e1009618.	2.1	20
608	New Prospects for Ultra-High-Field Magnetic Resonance Imaging in Multiple Sclerosis. Investigative Radiology, 2021, 56, 773-784.	3.5	19
609	Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration. JAMA Neurology, 2021, 78, 842.	4.5	15
610	Serum neurofilament light chain and glial fibrillary acidic protein in AQP4â€IgGâ€seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. Journal of Neurochemistry, 2021, 159, 913-922.	2.1	11
611	Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.. Multiple Sclerosis and Related Disorders, 2021, 52, 103003.	0.9	3
612	Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies. International Journal of Molecular Sciences, 2021, 22, 7536.	1.8	6
613	The Involvement of Lactosylceramide in Central Nervous System Inflammation Related to Neurodegenerative Disease. Frontiers in Aging Neuroscience, 2021, 13, 691230.	1.7	15
614	Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells. Vaccines, 2021, 9, 736.	2.1	1
615	Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?. Frontiers in Immunology, 2021, 12, 661882.	2.2	36
616	Live imaging of remyelination in the adult mouse corpus callosum. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	10
617	Association of clinical epidemiological factors to polypharmacy among patients with multiple sclerosis: real-life data. ABCS Health Sciences, 0, 46, .	0.3	0

#	Article	IF	Citations
618	The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis. Frontiers in Immunology, 2021, 12, 665718.	2.2	38
619	Stem Cell Therapies for Progressive Multiple Sclerosis. Frontiers in Cell and Developmental Biology, 2021, 9, 696434.	1.8	25
620	Quantifying myelin in crossing fibers using diffusionâ€prepared phase imaging: Theory and simulations. Magnetic Resonance in Medicine, 2021, 86, 2618-2634.	1.9	2
621	Hygiene hypothesis and autoimmune diseases: A narrative review of clinical evidences and mechanisms. Autoimmunity Reviews, 2021, 20, 102845.	2.5	24
622	Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America. Neurological Research, 2021, 43, 1081-1086.	0.6	8
623	Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 1834-1848.	2.1	11
624	Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 895-911.	1.4	7
625	Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2021, 79, 598-606.	0.3	1
626	Firstâ€line therapies in lateâ€onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123.	1.7	17
627	Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinsonâ€™s Disease. Current Pharmaceutical Design, 2021, 27, 4008-4016.	0.9	11
628	MANF Is Neuroprotective in Early Stages of EAE, and Elevated in Spinal White Matter by Treatment With Dexamethasone. Frontiers in Cellular Neuroscience, 2021, 15, 640084.	1.8	7
629	Prophylactic exposure to oral riluzole reduces the clinical severity and immune-related biomarkers of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2021, 356, 577603.	1.1	6
630	MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 561-572.	1.4	5
631	Interleukin-1 receptor antagonist: An exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 103006.	0.9	11
632	Oligodendrocytes and Microglia: Key Players in Myelin Development, Damage and Repair. Biomolecules, 2021, 11, 1058.	1.8	33
633	Massage therapy as a complementary and alternative approach for people with multiple sclerosis: a systematic review. Disability and Rehabilitation, 2022, 44, 5758-5769.	0.9	5
634	Unveiling the relationship between autonomic involvement, fatigue, and cognitive dysfunction in early relapsingâ€“remitting multiple sclerosis. Neurological Sciences, 2021, 42, 4281-4287.	0.9	3
635	Sphingosine kinase 2 is essential for remyelination following cuprizone intoxication. Glia, 2021, 69, 2863-2881.	2.5	12

#	Article	IF	Citations
636	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 831-841.	1.4	6
637	Geographic heterogeneity in the association of varicella-zoster virus seropositivity and multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 53, 103024.	0.9	8
638	Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study â€˜TOPICS Greeceâ€™. Clinical Drug Investigation, 2021, 41, 865-874.	1.1	5
639	Oligodendroglial ring finger protein Rnf43 is an essential injury-specific regulator of oligodendrocyte maturation. Neuron, 2021, 109, 3104-3118.e6.	3.8	21
640	BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis. Brain, 2021, 144, 2291-2301.	3.7	13
641	Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1054.	3.1	0
642	Serum Anti-oligodendrocyte Autoantibodies in Patients With Multiple Sclerosis Detected by a Tissue-Based Immunofluorescence Assay. Frontiers in Neurology, 2021, 12, 681980.	1.1	3
643	Self-management, self-esteem and their associations with psychological well-being in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103069.	0.9	1
644	An ID-Associated Application to Facilitate Patient-Tailored Management of Multiple Sclerosis. Brain Sciences, 2021, 11, 1061.	1.1	1
645	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. Neurology, 2021, 97, e1334-e1342.	1.5	12
646	Prediction of unenhanced lesion evolution in multiple sclerosis using radiomics-based models: a machine learning approach. Multiple Sclerosis and Related Disorders, 2021, 53, 102989.	0.9	13
647	Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population. Multiple Sclerosis and Related Disorders, 2021, 53, 103021.	0.9	8
648	Clinical practice patterns in multiple sclerosis management: Mexican consensus recommendations. Multiple Sclerosis and Related Disorders, 2021, 53, 103053.	0.9	2
649	Potential Roles of Extracellular Vesicles as Biomarkers and a Novel Treatment Approach in Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 9011.	1.8	16
650	TREM2-dependent lipid droplet biogenesis in phagocytes is required for remyelination. Journal of Experimental Medicine, 2021, 218, .	4.2	68
651	Walking with UAN.GO Exoskeleton: Training and Compliance in a Multiple Sclerosis Patient. Neurology International, 2021, 13, 428-438.	1.3	2
652	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Multiple Sclerosis and Related Disorders, 2021, 53, 103076.	0.9	13
654	Increased Serum Neurofilament Light and Thin Ganglion Cellâ€“Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29

#	Article	IF	Citations
656	Outcome measures assisting treatment optimization in multiple sclerosis. Journal of Neurology, 2022, 269, 1282-1297.	1.8	2
659	Is there a relationship between fall status, cognition and cerebellar lobule volume in patients with multiple sclerosis?. Applied Neuropsychology Adult, 2023, 30, 535-545.	0.7	0
660	Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert Review of Clinical Immunology, 2021, 17, 883-903.	1.3	6
661	Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care. Multiple Sclerosis and Related Disorders, 2021, 53, 103038.	0.9	4
662	Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis. Annals of Neurology, 2021, 90, 558-567.	2.8	8
663	Oligodendrocytes, BK channels and remyelination. F1000Research, 2021, 10, 781.	0.8	0
664	Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a caseâ€“control study. Neurological Sciences, 2022, 43, 2601-2609.	0.9	5
665	Potent T cellâ€mediated antiâ€inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	9
666	Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Current Pharmaceutical Design, 2022, 28, 428-436.	0.9	10
667	Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera. Nature Communications, 2021, 12, 5736.	5.8	21
668	Bcl6 controls meningeal Th17â€“B cell interaction in murine neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	13
669	Migraine in multiple sclerosis and other chronic inflammatory diseases. Revue Neurologique, 2021, 177, 816-820.	0.6	12
670	Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 54, 103103.	0.9	11
671	Follicular Helper CD4+ T Cells, Follicular Regulatory CD4+ T Cells, and Inducible Costimulator and Their Roles in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Mediators of Inflammation, 2021, 2021, 1-10.	1.4	14
672	Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2579-2588.	2.1	17
673	Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsingâ€Remitting Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2589-2597.	2.1	0
674	Effect of Exercise on Fatigue in Multiple Sclerosis: A Network Meta-analysis Comparing Different Types of Exercise. Archives of Physical Medicine and Rehabilitation, 2022, 103, 970-987.e18.	0.5	13
675	Cost of illness in multiple sclerosis by disease characteristics â€“ A review of reviews. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 177-195.	0.7	10

#	Article	IF	Citations
676	Altered sensorimotor integration in multiple sclerosis: A combined neurophysiological and functional MRI study. Clinical Neurophysiology, 2021, 132, 2191-2198.	0.7	7
677	Explainable neural networks that simulate reasoning. Nature Computational Science, 2021, 1, 607-618.	3.8	20
678	Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. Multiple Sclerosis Journal, 2022, 28, 900-909.	1.4	4
679	Secondary Impacts of COVID-19 Pandemic in Fatigue, Self-Compassion, Physical and Mental Health of People with Multiple Sclerosis and Caregivers: The Teruel Study. Brain Sciences, 2021, 11, 1233.	1.1	7
680	Irisin levels in the serum and cerebrospinal fluid of patients with multiple sclerosis and the expression and distribution of irisin in experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2021, 206, 208-215.	1.1	5
681	Nanosystems and exosomes as future approaches in treating multiple sclerosis. European Journal of Neuroscience, 2021, 54, 7377-7404.	1.2	9
682	Pro-Inflammatory Cytokines and Antibodies Induce hnRNP A1 Dysfunction in Mouse Primary Cortical Neurons. Brain Sciences, 2021, 11, 1282.	1.1	6
683	Assessment of commonly used methods to determine myelin-reactivity of T cells in multiple sclerosis. Clinical Immunology, 2021, 230, 108817.	1.4	4
684	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 729-738.	4.9	89
685	Suggesting 7,8-dihydroxyflavone as a promising nutraceutical against CNS disorders. Neurochemistry International, 2021, 148, 105068.	1.9	13
686	Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. International Journal of Molecular Sciences, 2021, 22, 9753.	1.8	17
687	Plasma circulating vitamin C levels and risk of multiple sclerosis: a two-sample Mendelian randomization analysis. Multiple Sclerosis and Related Disorders, 2021, 56, 103267.	0.9	1
688	Influenza vaccination status in multiple sclerosis patients from Latin America. Journal of NeuroVirology, 2021, 27, 750-754.	1.0	2
689	<scp>7T MRI</scp> Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions. Annals of Neurology, 2021, 90, 612-626.	2.8	37
690	A lymphocyteâ€“microgliaâ€“astrocyte axis in chronic active multiple sclerosis. Nature, 2021, 597, 709-714.	13.7	307
691	Implementation of a pharmacistâ€managed population health monitoring tool for disease modifying therapies in treatment of patients with multiple sclerosis in a veterans affairs medical center. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	0.5	0
692	Dysfunction of oligodendrocyte inwardly rectifying potassium channel in a rat model of amyotrophic lateral sclerosis. European Journal of Neuroscience, 2021, 54, 6339-6354.	1.2	7
693	MiRâ€142â€3p regulates synaptopathyâ€driven disease progression in multiple sclerosis. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	13

#	Article	IF	Citations
694	Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1273-1295.	0.5	6
695	AZD8055 ameliorates experimental autoimmune encephalomyelitis via the mTOR/ROS/NLRP3 pathway. Biochemical and Biophysical Research Communications, 2021, 573, 27-34.	1.0	6
696	Therapeutic plasma exchange in MS refractory relapses: Long-term outcome. Multiple Sclerosis and Related Disorders, 2021, 55, 103168.	0.9	3
697	Choroid Plexus Enlargement in Inflammatory Multiple Sclerosis: 3.0-T MRI and Translocator Protein PET Evaluation. Radiology, 2021, 301, 166-177.	3.6	74
698	Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation. Journal of the Neurological Sciences, 2021, 429, 118072.	0.3	7
699	Natalizumab subcutaneous injection for the treatment of relapsing multiple sclerosis patients: A new delivery route. Multiple Sclerosis and Related Disorders, 2021, 55, 103179.	0.9	5
700	Multiple sclerosis incidence and prevalence in Poland: Data from administrative health claims. Multiple Sclerosis and Related Disorders, 2021, 55, 103162.	0.9	10
701	Genetically predicted circulating homocysteine, vitamin B12, and folate levels and risk of multiple sclerosis: evidence from a two-sample Mendelian randomization analysis. Multiple Sclerosis and Related Disorders, 2021, 56, 103255.	0.9	0
702	In vivo evidence of functional disconnection between brainstem monoaminergic nuclei and brain networks in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103224.	0.9	4
703	Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab. Multiple Sclerosis and Related Disorders, 2021, 56, 103266.	0.9	1
705	An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview. Cellular and Molecular Life Sciences, 2021, 78, 3181-3203.	2.4	34
706	Neuroprotective Effect of Apolipoprotein D in Cuprizone-Induced Cell Line Models: A Potential Therapeutic Approach for Multiple Sclerosis and Demyelinating Diseases. International Journal of Molecular Sciences, 2021, 22, 1260.	1.8	6
707	EVALUATION OF EATING ATTITUDES IN PATIENTS ATTENDING MULTIPLE SCLEROSIS PATIENT CAMP. Samsun SaÄŸlÄ±k Bilimleri Dergisi, 0, , .	0.3	1
708	In vivo detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy. Theranostics, 2021, 11, 2490-2504.	4.6	10
709	In vivo tensor-valued diffusion MRI of focal demyelination in white and deep grey matter of rodents. NeuroImage: Clinical, 2021, 30, 102675.	1.4	7
710	Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability. NeuroImage: Clinical, 2021, 30, 102680.	1.4	13
711	Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis. Neurotherapeutics, 2021, 18, 387-400.	2.1	12
712	Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642097564.	1.5	9

#	Article	IF	Citations
713	3D Quantitative Synthetic MRI in the Evaluation of Multiple Sclerosis Lesions. American Journal of Neuroradiology, 2021, 42, 471-478.	1.2	16
714	A Structural Causal Model for MR Images of Multiple Sclerosis. Lecture Notes in Computer Science, 2021, , 782-792.	1.0	9
716	The awareness and knowledge differences of multiple sclerosis among health-related students in Umm Al-Qura University, Makkah City, Saudi Arabia: an analytic cross-sectional study. Journal of Biochemical and Clinical Genetics, 0, , 1046-1050.	0.1	1
717	Oligodendroglial glycolipids in (Re)myelination: implications for multiple sclerosis research. Natural Product Reports, 2021, 38, 890-904.	5.2	7
718	Patterns of cortical grey matter thickness reduction in multiple sclerosis. Brain and Behavior, 2021, 11, e02050.	1.0	11
719	Adaptive changes in muscle activity after cryotherapy treatment: Potential mechanism for improvement the functional state in patients with multiple sclerosis. NeuroRehabilitation, 2021, 48, 119-131.	0.5	4
720	Study protocol: randomised controlled trial evaluating exercise therapy as a supplemental treatment strategy in early multiple sclerosis: the Early Multiple Sclerosis Exercise Study (EMSES). BMJ Open, 2021, 11, e043699.	0.8	11
722	Relationships between accelerometer-measured and multiple sclerosis: a 2-sample Mendelian randomization study. Neurological Sciences, 2021, 42, 3337-3341.	0.9	3
723	Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel. Frontiers in Neurology, 2020, 11, 612304.	1.1	11
724	Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis. Brain, 2021, 144, 3664-3673.	3.7	13
725	Multifaceted Involvement of Microglia in Gray Matter Pathology in Multiple Sclerosis. Stem Cells, 2021, 39, 993-1007.	1.4	15
726	Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation. Advances in Experimental Medicine and Biology, 2019, 1161, 169-191.	0.8	62
727	EntzÃ¼ndliche Erkrankungen. , 2019, , 51-98.		2
728	Extrinsic Factors Driving Oligodendrocyte Lineage Cell Progression in CNS Development and Injury. Neurochemical Research, 2020, 45, 630-642.	1.6	23
729	MAFG-driven astrocytes promote CNS inflammation. Nature, 2020, 578, 593-599.	13.7	282
730	Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy. Scientific Data, 2018, 5, 180145.	2.4	12
731	Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs. RSC Drug Discovery Series, 2019, , 1-32.	0.2	6
732	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38

#	Article	IF	Citations
741	Neuron-specific PERK inactivation exacerbates neurodegeneration during experimental autoimmune encephalomyelitis. JCI Insight, 2019, 4, .	2.3	16
742	Deficiency of Socs3 leads to brain-targeted experimental autoimmune encephalomyelitis via enhanced neutrophil activation and ROS production. JCI Insight, 2019, 4, .	2.3	35
743	Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight, 2019, 4, .	2.3	79
744	Potential role of iron in repair of inflammatory demyelinating lesions. Journal of Clinical Investigation, 2019, 129, 4365-4376.	3.9	45
745	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. Journal of Clinical Investigation, 2020, 130, 3467-3482.	3.9	109
746	Ultra-high-field 7-T MRI in multiple sclerosis and other demyelinating diseases: from pathology to clinical practice. European Radiology Experimental, 2020, 4, 59.	1.7	23
747	Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 611-635.	0.4	15
748	Pediatric Central Nervous System Demyelinating Diseases. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 793-814.	0.4	9
749	Functional and self-care capacity of people with multiple sclerosis. Revista Latino-Americana De Enfermagem, 2019, 27, e3183.	0.4	8
750	Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis. Aging, 2020, 12, 15134-15156.	1.4	8
751	Microglial process convergence on axonal segments in health and disease. Neuroimmunology and Neuroinflammation, 2020, 2020, 23-39.	1.4	10
752	Multiple Sclerosis: Lipids, Lymphocytes, and Vitamin D. Immunometabolism, 2020, 2, .	0.7	25
753	Feasibility of Real Time Internet-Based Teleconsultation in Patients With Multiple Sclerosis: Interventional Pilot Study. Journal of Medical Internet Research, 2020, 22, e18178.	2.1	24
754	Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study. JMIR MHealth and UHealth, 2020, 8, e22108.	1.8	55
755	Alterations of the Fecal Microbiota in Chinese Patients With Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 590783.	2.2	43
756	Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease. Antioxidants, 2021, 10, 28.	2.2	7
757	Better Objective Sleep Was Associated with Better Subjective Sleep and Physical Activity; Results from an Exploratory Study under Naturalistic Conditions among Persons with Multiple Sclerosis. International Journal of Environmental Research and Public Health, 2020, 17, 3522.	1.2	13
758	Relationship between Fatigue and Physical Activity in a Polish Cohort of Multiple Sclerosis Patients. Medicina (Lithuania), 2020, 56, 726.	0.8	11

#	Article	IF	Citations
759	Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients. Journal of Immunology, 2020, 204, 1101-1110.	0.4	18
760	Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. Neural Regeneration Research, 2019, 14, 77.	1.6	4
761	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regeneration Research, 2019, 14, 373.	1.6	114
762	Unfolded protein response in myelin disorders. Neural Regeneration Research, 2020, 15, 636.	1.6	31
763	Magnetic Resonance Imaging of Spinal Cord Lesions in Patients with Multiple Sclerosis in Saskatchewan, Canada. International Journal of MS Care, 2021, 23, 47-52.	0.4	2
764	Multiple sclerosis. Mental Health Clinician, 2019, 9, 349-358.	0.5	12
765	Assisting the diagnosis of multiple sclerosis using a set of regional brain volumes: A classification model for patients and healthy controls. Informatics in Medicine Unlocked, 2021, 26, 100766.	1.9	2
766	Experimental autoimmune encephalomyelitis inhibited by huangqi guizhi wuwu decoction via th2 cytokine enhancement. World Journal of Traditional Chinese Medicine, 2021, 7, 467.	0.9	7
767	Evaluation of Treatment Practices for Urinalyses and Urine Cultures at an Outpatient Multiple Sclerosis Clinic. International Journal of MS Care, 2021, 23, 234-238.	0.4	3
768	Neuronal cholesterol synthesis is essential for repair of chronically demyelinated lesions in mice. Cell Reports, 2021, 37, 109889.	2.9	23
769	Linking immune-mediated damage to neurodegeneration in multiple sclerosis: could network-based MRI help?. Brain Communications, 2021, 3, fcab237.	1.5	9
770	Growth Factors and Their Roles in Multiple Sclerosis Risk. Frontiers in Immunology, 2021, 12, 768682.	2.2	4
771	Rim lesions are demonstrated in early relapsingâ€“remitting multiple sclerosis using 3ÂT-based susceptibility-weighted imaging in a multi-institutional setting. Neuroradiology, 2022, 64, 109-117.	1.1	12
772	The Immune Response in Multiple Sclerosis. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 121-139.	9.6	96
773	Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Multiple Sclerosis and Related Disorders, 2022, 57, 103333.	0.9	4
774	Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways. Pharmaceuticals, 2021, 14, 1057.	1.7	27
775	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. Cell Reports Medicine, 2021, 2, 100424.	3.3	26
776	Retinal Oxygen Metabolism and Haemodynamics in Patients With Multiple Sclerosis and History of Optic Neuritis. Frontiers in Neuroscience, 2021, 15, 761654.	1.4	7

#	Article	IF	Citations
777	Measuring treatment response to advance precision medicine for multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 2166-2173.	1.7	6
778	Application of definitions for conversion to secondary progressive MS in a Danish nationwide population. Multiple Sclerosis and Related Disorders, 2021, 56, 103319.	0.9	6
779	Reactive balance responses to a trip and slip during gait in people with multiple sclerosis. Clinical Biomechanics, 2021, 90, 105511.	0.5	3
780	TRPM2 contributes to neuroinflammation and cognitive deficits in a cuprizone-induced multiple sclerosis model via NLRP3 inflammasome. Neurobiology of Disease, 2021, 160, 105534.	2.1	16
782	Myelopathies. , 2019, , 347-375.		0
783	Flammer Syndrome and Autoimmune Inflammatory Conditions of the Central Nervous System: Multifactorial Interrelations. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 145-163.	0.6	1
784	Drugs for Soft Tissue Autoimmune Disorders. , 2019, , 751-775.		0
785	THE FIRST DOSING OCRELIZUMAB EXPERIENCE OF A NEUROLOGY CLINIC: A RETROSPECTIVE STUDY. Noropsikiyatri Arsivi, 2019, 58, 52-56.	0.2	1
788	Neurourology in Multiple Sclerosis and Other Demyelinating Disorders. , 2020, , 117-125.		0
790	Magnetic Resonance Imaging and Analysis in Multiple Sclerosis. Current Clinical Neurology, 2020, , 109-136.	0.1	3
791	Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients. , 2019, 10, 200.		2
792	Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis. European Journal of Hospital Pharmacy, 2021, 28, 112-114.	0.5	2
796	AvaliaÃ§Ã£o da qualidade de vida em portadores de esclerose mÃºltipla: impacto da fadiga, ansiedade e depressÃ£o. Fisioterapia E Pesquisa, 2019, 26, 339-345.	0.3	4
797	Intermediate Uveitis. , 2020, , 259-268.		0
798	Retinal Nerve Fiber Layer Thickness Correlates with Serum and Cerebrospinal Fluid Neurofilament and Nitrotyrosine Levels and is Associated with Current Disability in Multiple Sclerosis. Noropsikiyatri Arsivi, 2020, 58, 34-40.	0.2	7
799	Hindsight Is 20/20. Journal of Hospital Medicine, 2020, 15, 245-249.	0.7	0
801	The experience of using ocrelizumab in routine practice. Meditsinskiy Sovet, 2020, , 76-80.	0.1	0
802	Oligodendrocyte ARNT2 expression is altered in models of MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e745.	3.1	2

#	Article	IF	Citations
803	Upper Limb Dexterity in Patients with Multiple Sclerosis. International Journal of MS Care, 2021, 23, 79-84.	0.4	9
807	El rol del ejercicio fÃsico en la nicturia de los pacientes con esclerosis mÃºltiple. Revista Medica Sinergia, 2020, 5, e419.	0.0	0
808	A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis. CNS and Neurological Disorders - Drug Targets, 2022, 21, 160-187.	0.8	3
809	Oral Colonization by Candida Species in Patients with Multiple Sclerosis. Mycopathologia, 2020, 185, 983-991.	1.3	3
810	The Prevalence of Sexual Dysfunction in Patients With Multiple Sclerosis in Cyprus: A Cross-sectional Study. Journal of Neuroscience Nursing, 2020, 52, 302-307.	0.7	5
811	Dynamic topology analysis for spatial patterns of multifocal lesions on MRI. Medical Image Analysis, 2022, 76, 102267.	7.0	2
813	Personalized Therapy of Neurological Disorders. , 2021, , 213-262.		1
816	SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting. Heliyon, 2020, 6, e05819.	1.4	1
819	The risk of polypharmacy, comorbidities and drugâ€“drug interactions in women of childbearing age with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096950.	1.5	9
821	Immunopathogenesis. Current Clinical Neurology, 2020, , 45-69.	0.1	2
822	Multiple Sklerose und andere Autoimmunerkrankungen. , 2020, , 431-440.		0
823	Immunsuppressiva, Immunmodulatoren. , 2020, , 229-242.		0
824	Can Wearing a Face Mask Protect from COVID-19? A Systematic Review. Iranian Journal of Medical Microbiology, 2020, 14, 101-107.	0.1	0
825	Neutralization of Hv1/HVCN1 With Antibody Enhances Microglia/Macrophages Myelin Clearance by Promoting Their Migration in the Brain. Frontiers in Cellular Neuroscience, 2021, 15, 768059.	1.8	7
826	Virtual Reality-Based Therapy Improves Fatigue, Impact, and Quality of Life in Patients with Multiple Sclerosis. A Systematic Review with a Meta-Analysis. Sensors, 2021, 21, 7389.	2.1	30
827	Retinal imaging biomarkers of neurodegenerative diseases. Australasian journal of optometry, The, 2022, 105, 194-204.	0.6	14
828	The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. Cells, 2021, 10, 3056.	1.8	17
829	Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103366.	0.9	8

#	Article	IF	Citations
830	Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. Frontiers in Aging Neuroscience, 2021, 13, 766587.	1.7	13
831	MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis. Brain Communications, 2021, 3, fcab249.	1.5	10
832	Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study. European Neurology, 2022, 85, 104-111.	0.6	4
833	Molecular characterization of the gut microbiome in egyptian patients with remitting relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103354.	0.9	5
834	Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. Frontiers in Immunology, 2021, 12, 757302.	2.2	27
837	The pattern of thyroiditis in multiple sclerosis: a cross-sectional study in a tertiary care hospital in Egypt. The Egyptian Journal of Internal Medicine, 2020, 32, 17.	0.3	3
840	Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode. JAMA Network Open, 2020, 3, e2016278.	2.8	18
841	Dihydroartemisinin ameliorates murine experimental autoimmune encephalomyelitis through enhancing co-inhibitory signals. Materials Express, 2020, 10, 1824-1830.	0.2	1
842	Therapeutic effect of transplanted umbilical cord mesenchymal stem cells in a cynomolgus monkey model of multiple sclerosis. American Journal of Translational Research (discontinued), 2019, 11, 2516-2531.	0.0	6
843	A proinflammatory diet is associated with an increased likelihood of first clinical diagnosis of central nervous system demyelination in women. Multiple Sclerosis and Related Disorders, 2022, 57, 103428.	0.9	5
844	Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-Î² in a Preclinical Model of Multiple Sclerosis. Biomedicines, 2021, 9, 1758.	1.4	14
845	Oligodendrocytes, BK channels and the preservation of myelin. F1000Research, 0, 10, 781.	0.8	2
847	Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103401.	0.9	4
848	Siponimod for multiple sclerosis. The Cochrane Library, 2021, 2021, CD013647.	1.5	5
849	Optical coherence tomography in multiple sclerosis: A 3â€year prospective multicenter study. Annals of Clinical and Translational Neurology, 2021, 8, 2235-2251.	1.7	36
850	Effects of Orally Administered Cannabidiol on Neuroinflammation and Intestinal Inflammation in the Attenuation of Experimental Autoimmune Encephalomyelitis. Journal of NeuroImmune Pharmacology, 2022, 17, 15-32.	2.1	21
851	Circulatory antioxidant and oxidative stress markers are in correlation with demographics but not cognitive functions in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 57, 103432.	0.9	3
852	Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Quality of Life Research, 2022, 31, 1799-1805.	1.5	6

#	Article	IF	Citations
853	Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. Journal of Clinical Medicine, 2021, 10, 5401.	1.0	6
855	The role of neural stem cells in regulating glial scar formation and repair. Cell and Tissue Research, 2022, 387, 399-414.	1.5	20
856	Replenishing the Aged Brains: Targeting Oligodendrocytes and Myelination?. Frontiers in Aging Neuroscience, 2021, 13, 760200.	1.7	10
857	Neural Processes of Psychological Stress and Relaxation Predict the Future Evolution of Quality of Life in Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 753107.	1.1	7
858	Paramagnetic Rim Lesions in Multiple Sclerosis: Comparison of Visualization at 1.5-T and 3-T MRI. American Journal of Roentgenology, 2022, 219, 120-131.	1.0	22
859	Combining Human Genetics of Multiple Sclerosis with Oxidative Stress Phenotype for Drug Repositioning. Pharmaceutics, 2021, 13, 2064.	2.0	3
862	Multiple Sclerosis flare-ups Diagnostic and Management Approach in Emergency Department, Review Article. World Journal of Environmental Biosciences, 2021, 10, 9-12.	0.1	0
864	Neurological applications of hyperpolarized 13C MR. Advances in Magnetic Resonance Technology and Applications, 2021, 3, 187-215.	0.0	0
865	wSDTNBI: a novel network-based inference method for virtual screening. Chemical Science, 2022, 13, 1060-1079.	3.7	11
866	Novel contributors to B cell activation during inflammatory CNS demyelination; An oNGOing process. International Journal of Medical Sciences, 2022, 19, 164-174.	1.1	1
867	Sarcopenia in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103471.	0.9	11
868	Establishment of Human Induced Pluripotent Stem Cells from Multiple Sclerosis Patients. Methods in Molecular Biology, 2021, , 43-67.	0.4	2
869	Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders. Handbook of Experimental Pharmacology, 2021, , 245-265.	0.9	1
870	REVISION OF MULTIPLE SCLEROSIS CASES ACCORDING TO NEW 2017 MCDONALD CRITERIA AMONG DIAGNOSED PATIENTS IN SULAIMANI CITY. Journal of Sulaimani Medical College, 2021, 11, 323-333.	0.0	2
871	The Efficacy of Fecal Microbiota Transplantation in Experimental Autoimmune Encephalomyelitis: Transcriptome and Gut Microbiota Profiling. Journal of Immunology Research, 2021, 2021, 1-12.	0.9	17
872	Immunomodulatory effects of parasites on autoimmunity. , 2022, , 395-424.		2
873	A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector. Neurology and Therapy, 2022, 11, 373.	1.4	2
874	Estimation and Testing of Wilcoxonâ€“Mannâ€“Whitney Effects in Factorial Clustered Data Designs. Symmetry, 2022, 14, 244.	1.1	3

#	Article	IF	Citations
875	DICAM, a molecular passport for T _H 17 cell entry into the brain. Science Translational Medicine, 2022, 14, eabm7204.	5.8	1
878	Lifestyle and complementary therapies in multiple sclerosis guidelines: Systematic review. Acta Neurologica Scandinavica, 2022, 145, 379-392.	1.0	7
879	Is surgery beneficial for patients with concurrent multiple sclerosis and degenerative cervical myelopathy? A review of literature. Brain and Spine, 2022, 2, 100870.	0.0	3
881	Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
882	Multiple sclerosis and inflammatory bowel disease: AÂsystematic review and metaâ€analysis. Annals of Clinical and Translational Neurology, 2022, 9, 132-140.	1.7	21
883	Therapeutic Effects of the Pilates Method in Patients with Multiple Sclerosis: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 683.	1.0	12
884	Oligodendrocytes and myelin: Active players in neurodegenerative brains?. Developmental Neurobiology, 2022, 82, 160-174.	1.5	17
885	Integrin Signaling in the Central Nervous System in Animals and Human Brain Diseases. International Journal of Molecular Sciences, 2022, 23, 1435.	1.8	13
886	Multiple Sclerosis and Telerehabilitation. , 2022, , 119-134.		0
887	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science, 2022, 375, 296-301.	6.0	892
888	Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patients. Pharmacogenomics, 2022, 23, 161-171.	0.6	1
889	Manipulating Macrophage/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis. Pharmaceutics, 2022, 14, 344.	2.0	13
890	Myocardial infarction and stroke risks in multiple sclerosis patients: A two-sample Mendelian randomization study. Multiple Sclerosis and Related Disorders, 2022, 58, 103501.	0.9	3
891	Estimation the medical cost of multiple sclerosis in Iran; 2019â€“2020. BMC Health Services Research, 2022, 22, 137.	0.9	3
892	ILF3 represses repeat-derived microRNAs targeting RIG-I mediated type I interferon response. Journal of Molecular Biology, 2022, 434, 167469.	2.0	2
893	JAB1 deletion in oligodendrocytes causes senescence-induced inflammation and neurodegeneration in mice. Journal of Clinical Investigation, 2022, 132, .	3.9	12
894	Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis. Multiple Sclerosis and Related Disorders, 2022, 59, 103555.	0.9	3
895	Cordycepin prevents and ameliorates experimental autoimmune encephalomyelitis by inhibiting leukocyte infiltration and reducing neuroinflammation. Biochemical Pharmacology, 2022, 197, 114918.	2.0	2

#	Article	IF	Citations
896	Soluble TREM2: Innocent bystander or active player in neurological diseases?. Neurobiology of Disease, 2022, 165, 105630.	2.1	41
897	The C-type lectin receptor Clec1A plays an important role in the development of experimental autoimmune encephalomyelitis by enhancing antigen presenting ability of dendritic cells and inducing inflammatory cytokine IL-17. Experimental Animals, 2022, 71, 288-304.	0.7	2
898	Intertwined like a double helix: A metaâ€synthesis of the qualitative literature examining the experiences of living with someone with multiple sclerosis. Health Expectations, 2022, 25, 803-822.	1.1	3
899	Next-generation sequencing of the whole mitochondrial genome identifies functionally deleterious mutations in patients with multiple sclerosis. PLoS ONE, 2022, 17, e0263606.	1.1	10
900	Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2022, 19, 42.	3.1	8
901	Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 798300.	2.2	12
902	Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. Journal of Neuroinflammation, 2022, 19, 45.	3.1	51
903	VAILABILITY OF FIBRINOGEN/ALBUMIN RATIO IN MS ATTACK. Multiple Sclerosis and Related Disorders, 2022, 60, 103674.	0.9	5
904	Identification and Clinical Validation of Key Extracellular Proteins as the Potential Biomarkers in Relapsing-Remitting Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 753929.	2.2	20
905	Towards Multimodal Machine Learning Prediction of Individual Cognitive Evolution in Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 1349.	1.1	10
906	Cytokine Storm and Failed Resolution in COVID-19: Taking a Cue from Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2021, 1352, 211-222.	0.8	0
907	Function and therapeutic value of astrocytes in neurological diseases. Nature Reviews Drug Discovery, 2022, 21, 339-358.	21.5	160
908	The neuroprotective effects of icariin on ageing, various neurological, neuropsychiatric disorders, and brain injury induced by radiation exposure. Aging, 2022, 14, 1562-1588.	1.4	10
909	Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2022, 19, 52.	3.1	12
910	Effects of COVID-19 on Multiple Sclerosis Relapse: A Comprehensive Review. International Journal of Medical Students, 0, , .	0.2	1
911	Short-Range Structural Connections Are More Severely Damaged in Early-Stage MS. American Journal of Neuroradiology, 2022, 43, 361-367.	1.2	4
912	Diverse injury responses of human oligodendrocyte to mediators implicated in multiple sclerosis. Brain, 2022, 145, 4320-4333.	3.7	9
913	Targeting IFN-Î» Signaling Promotes Recovery from Central Nervous System Autoimmunity. Journal of Immunology, 2022, 208, 1341-1351.	0.4	6

#	Article	IF	Citations
914	Optical coherence tomography in neurodegenerative disorders. Arquivos De Neuro-Psiquiatria, 2022, 80, 180-191.	0.3	5
915	B cell-dependent EAE induces visual deficits in the mouse with similarities to human autoimmune demyelinating diseases. Journal of Neuroinflammation, 2022, 19, 54.	3.1	6
916	Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes. Arquivos De Neuro-Psiquiatria, 2022, 80, 399-404.	0.3	2
917	Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis. Medicine (United States), 2022, 101, .	0.4	1
918	<scp>MS</scp>â€Driven Metabolic Alterations Are Recapitulated in <scp>iPSC</scp>â€Derived Astrocytes. Annals of Neurology, 2022, 91, 652-669.	2.8	5
919	The Application of Diffusion Kurtosis Imaging on the Heterogeneous White Matter in Relapsing-Remitting Multiple Sclerosis. Frontiers in Neuroscience, 2022, 16, 849425.	1.4	6
920	Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland. Wellcome Open Research, 0, 7, 94.	0.9	6
921	Quantitative susceptibility mapping versus phase imaging to identify multiple sclerosis iron rim lesions with demyelination. Journal of Neuroimaging, 2022, 32, 667-675.	1.0	11
922	Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult. Brain Pathology, 2022, 32, e13064.	2.1	5
923	Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells. Glia, 2022, 70, 1191-1209.	2.5	17
924	Innovating Care in Multiple Sclerosis: Feasibility of Synchronous Internet-Based Teleconsultation for Longitudinal Clinical Monitoring. Journal of Personalized Medicine, 2022, 12, 433.	1.1	3
925	Mendelian Randomization Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis. Frontiers in Neuroscience, 2022, 16, 817067.	1.4	9
926	Predictive MRI Biomarkers in MSâ€"A Critical Review. Medicina (Lithuania), 2022, 58, 377.	0.8	9
929	Multipl sklerozlu hastalarda dengenin deÄŸerlendirilmesinde Mini-BESTest ve manyetik rezonans gÃ¶rÃ¼ntÃ¼lemenin etkinliÄŸi. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
930	Late-Onset MS: Disease Course and Safety-Efficacy of DMTS. Frontiers in Neurology, 2022, 13, 829331.	1.1	19
931	The Complex Interplay Between Trait Fatigue and Cognition in Multiple Sclerosis. Psychologica Belgica, 2022, 62, 108.	1.0	7
932	The Shared Mechanism and Candidate Drugs of Multiple Sclerosis and SjÃ¶grenâ€™s Syndrome Analyzed by Bioinformatics Based on GWAS and Transcriptome Data. Frontiers in Immunology, 2022, 13, 857014.	2.2	8
934	The Role of Autophagy in the Function of CD4+ T Cells and the Development of Chronic Inflammatory Diseases. Frontiers in Pharmacology, 2022, 13, 860146.	1.6	9

#	Article	IF	Citations
936	Awareness of COVID-19 Symptoms, Risk Factors, and Vaccinations in Patients with Multiple Sclerosis. International Journal of Environmental Research and Public Health, 2022, 19, 3366.	1.2	1
937	Machine learning classification of multiple sclerosis patients based on raw data from an instrumented walkway. BioMedical Engineering OnLine, 2022, 21, 21.	1.3	9
938	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	4.9	27
939	Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. Journal of Neuroimaging, 2022, 32, 910-919.	1.0	2
940	Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies. Multiple Sclerosis and Related Disorders, 2022, 60, 103728.	0.9	1
941	Hitting the Bullseye: Endogenous Electrophiles Show Remarkable Nuance in Signaling Regulation. Chemical Research in Toxicology, 2022, 35, 1636-1648.	1.7	1
942	Inhibition of RIPK1 by ZJU-37 promotes oligodendrocyte progenitor proliferation and remyelination via NF-Î²B pathway. Cell Death Discovery, 2022, 8, 147.	2.0	4
943	The mechanistic target of rapamycin as a regulator of metabolic function in oligodendroglia during remyelination. Current Opinion in Pharmacology, 2022, 63, 102193.	1.7	2
944	Spermine alleviates experimental autoimmune encephalomyelitis via regulating T cell activation and differentiation. International Immunopharmacology, 2022, 107, 108702.	1.7	4
945	Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease. , 2022, 238, 108180.		5
946	Multipl Skleroz TanÄ±lÄ± Egzersiz AlÄ±ÅŸkanlÄ±ÄŸÄ± Olan ve Olmayan KadÄ±n Hastalarda Alt Ãœriner Sistem SemptomlarÄ± ve YaÅŸam Kalitesinin KarÅŞÄ±laÅŸtÄ±rÄ±lmasÄ±. Journal of Exercise Therapy and Rehabilitation, 0, , .	0.2	0
947	Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System. NeuroImmunoModulation, 2022, 29, 220-230.	0.9	7
948	Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia. International Journal of Environmental Research and Public Health, 2021, 18, 13261.	1.2	3
949	Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials. Frontiers in Immunology, 2021, 12, 795574.	2.2	11
950	Early firstâ€line treatment response and subsequent disability worsening in relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2022, 29, 1106-1116.	1.7	1
951	Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review. Multiple Sclerosis Journal, 2022, 28, 1382-1391.	1.4	3
952	Dataâ€driven myelin water imaging based on T ₁ and T ₂ relaxometry. NMR in Biomedicine, 2021, , e4668.	1.6	0
953	TNFÎ± in MS and Its Animal Models: Implications for Chronic Pain in the Disease. Frontiers in Neurology, 2021, 12, 780876.	1.1	9

#	Article	IF	Citations
954	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	2.9	38
955	Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment. Frontiers in Immunology, 2021, 12, 778204.	2.2	5
956	Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation. Brain, 2022, 145, 2008-2017.	3.7	5
957	Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 13419.	1.8	5
958	A Comparison of IgG Index and Oligoclonal Band in the Cerebrospinal Fluid for Differentiating between RRMS and NMOSD. Brain Sciences, 2022, 12, 69.	1.1	1
959	Altered Plasma Metabolic Profiles in Chinese Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 792711.	2.2	5
960	T-Cell Response against Varicella Zoster Virus in Patients with Multiple Sclerosis during Relapse and Remission. International Journal of Molecular Sciences, 2022, 23, 298.	1.8	1
961	Editorial Comment: Paramagnetic Rim Lesionsâ€"An Imaging Biomarker for Chronic Active Lesions in Multiple Sclerosis May Help to Advance Research in Progressive Disease. American Journal of Roentgenology, 2021, , .	1.0	0
963	Validity and Reliability of the Turkish Version of the Self-Reported Disability Status Scale in Persons with Multiple Sclerosis. BalÄ±kesir SaÄŸlÄ±k Bilimleri Dergisi, 0, , .	0.0	0
964	Emotional disorders associated to multiple sclerosis and psychological interventions: a literature review. Acta Marisiensis - Seria Medica, 2022, 68, 6-11.	0.2	0
965	Treatment Challenges in Multiple Sclerosis â€“ A Continued Role for Glatiramer Acetate?. Frontiers in Neurology, 2022, 13, 844873.	1.1	4
966	First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis. Brain Sciences, 2022, 12, 499.	1.1	2
967	Multiple Sclerosis is a Risk Factor for Hyperthyroidism and Interferon Beta Action on Thyroid Hormones via Novel Immuno-neuro-enzymological Mechanisms. Al Mustansiriyah Journal of Pharmaceutical Sciences, 2022, 20, 72-81.	0.3	0
968	Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl) Tj ETQq1 1 0.784314 rgBT /Overlock	1.7	3
969	Contact-Dependent Granzyme B-Mediated Cytotoxicity of Th17-Polarized Cells Toward Human Oligodendrocytes. Frontiers in Immunology, 2022, 13, 850616.	2.2	7
970	Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina. Clinical Neuropharmacology, 2022, 45, 45-51.	0.2	14
1024	Advanced <scp>MRI</scp> quantification of neuroinflammatory disorders. Journal of Neuroscience Research, 2022, 100, 1389-1394.	1.3	1
1025	Immune Cell Contributors to the Female Sex Bias in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Current Topics in Behavioral Neurosciences, 2022, , 333-373.	0.8	5

#	Article	IF	Citations
1026	Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of Efficacy. Therapeutic Innovation and Regulatory Science, 2022, 56, 873-882.	0.8	3
1027	Treatment of Experimental Autoimmune Encephalomyelitis using AAV Gene Therapy by blocking T-cell Costimulatory Pathways. Molecular Therapy - Methods and Clinical Development, 2022, , .	1.8	2
1028	SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation. Frontiers in Immunology, 2022, 13, 871276.	2.2	13
1030	A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210914.	0.5	2
1031	Reactive and Senescent Astroglial Phenotypes as Hallmarks of Brain Pathologies. International Journal of Molecular Sciences, 2022, 23, 4995.	1.8	18
1032	Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study. Journal of Neurology, 2022, 269, 4895-4908.	1.8	8
1033	Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. Value in Health, 2022, 25, 1489-1498.	0.1	2
1034	Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 677.	1.1	3
1035	Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies. Journal of Clinical Medicine, 2022, 11, 2509.	1.0	3
1036	Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heralding Prodrome. Frontiers in Neurology, 2022, 13, .	1.1	1
1037	Basal metabolic rate and risk of multiple sclerosis: a Mendelian randomization study. Metabolic Brain Disease, 2022, 37, 1855-1861.	1.4	4
1038	General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis. Vaccine, 2022, 40, 3236-3243.	1.7	1
1039	Dietary Supplementation With Acer truncatum Oil Promotes Remyelination in a Mouse Model of Multiple Sclerosis. Frontiers in Neuroscience, 2022, 16, 860280.	1.4	7
1040	Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials. Frontiers in Pharmacology, 2022, 13, .	1.6	2
1041	Pregnancy and Family Planning Considerations in Multiple Sclerosis. Current Obstetrics and Gynecology Reports, 2022, 11, 90-94.	0.3	1
1042	Matrine inhibits the Wnt3a/Î²-catenin/TCF7L2 signaling pathway in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2022, 367, 577876.	1.1	5
1043	miRNAs in multiple sclerosis: A clinical approach. Multiple Sclerosis and Related Disorders, 2022, 63, 103835.	0.9	2
1044	Comparative effectiveness of four exercise interventions followed by two years of exercise maintenance in multiple sclerosis: A randomized control trial. Archives of Physical Medicine and Rehabilitation, 2022, , .	0.5	3

#	Article	IF	Citations
1045	Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. International Journal of Environmental Research and Public Health, 2022, 19, 6069.	1.2	1
1046	STAT1 signaling protects self-reactive T cells from control by innate cells during neuroinflammation. JCI Insight, 2022, 7, .	2.3	5
1048	TGF-Î² as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications. Biomedicines, 2022, 10, 1206.	1.4	25
1049	Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103906.	0.9	1
1050	Comparative Profiling of TG2 and Its Effectors in Human Relapsing Remitting and Progressive Multiple Sclerosis. Biomedicines, 2022, 10, 1241.	1.4	3
1052	Preferences for Disease-Modifying Therapies in Argentina: Cross-Sectional Conjoint Analysis of Patients and Neurologists. Value in Health Regional Issues, 2022, 31, 93-100.	0.5	3
1053	Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. Frontiers in Neurology, 2022, 13, .	1.1	18
1054	Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	12
1055	Investigating the <scp>NLRP3</scp> inflammasome and its regulator <scp>miR</scp>â€223â€3p in multiple sclerosis and experimental demyelination. Journal of Neurochemistry, 2022, 163, 94-112.	2.1	4
1056	MicroRNAs and their Implications in CD4+ T-cells, Oligodendrocytes and Dendritic Cells in Multiple Sclerosis Pathogenesis. Current Molecular Medicine, 2023, 23, 630-647.	0.6	4
1057	Cognitive assessment of Brazilian patients with multiple sclerosis: weighing the impact of disability and depressive symptoms. Dementia E Neuropsychologia, 0, , .	0.3	0
1058	A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis. Neurology and Therapy, 2022, 11, 981-1042.	1.4	5
1059	Transparent Quality Optimization for Machine Learning-Based Regression in Neurology. Journal of Personalized Medicine, 2022, 12, 908.	1.1	0
1060	Metabolomics of Cerebrospinal Fluid in Multiple Sclerosis Compared With Healthy Controls: A Pilot Study. Frontiers in Neurology, 0, 13, .	1.1	4
1061	Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010â€“2019. Neurology and Therapy, 2022, 11, 1147-1165.	1.4	5
1062	Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis. Neurology, 2022, 99, .	1.5	7
1063	Experiences of persons with Multiple Sclerosis with lifestyle adjustmentâ€“A qualitative interview study. PLoS ONE, 2022, 17, e0268988.	1.1	5
1064	Therapeutic Advances in Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	28

#	Article	IF	Citations
1065	Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibodyâ€positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibodyâ€associated disease. Epilepsia, 2022, 63, 2173-2191.	2.6	12
1066	PECAM-1 Is Down-Regulated in Î³ÎT Cells during Remission, but Up-Regulated in Relapse of Multiple Sclerosis. Journal of Clinical Medicine, 2022, 11, 3210.	1.0	2
1067	Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis. Journal of Neurology, 2022, 269, 5436-5442.	1.8	6
1068	Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7â€…T MRI study. Brain, 2022, 145, 3522-3535.	3.7	6
1069	Thermoregulatory dynamics reveal sex-specific inflammatory responses to experimental autoimmune encephalomyelitis in mice: Implications for multiple sclerosis-induced fatigue in females. Brain, Behavior, & Immunity - Health, 2022, 23, 100477.	1.3	3
1070	Therapeutic role of nutraceuticals in the management of brain disorders. , 2022, , 127-161.		0
1071	Early Stage Detection of Multiple Sclerosis using FCNN. , 2022, , .		0
1072	Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis. Frontiers in Immunology, 0, 13, .	2.2	8
1073	Effects of Different Exercise Therapies on Balance Function and Functional Walking Ability in Multiple Sclerosis Disease Patientsâ€”A Network Meta-Analysis of Randomized Controlled Trials. International Journal of Environmental Research and Public Health, 2022, 19, 7175.	1.2	12
1074	Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study. Multiple Sclerosis Journal, 2022, 28, 2046-2056.	1.4	13
1075	Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nature Reviews Neurology, 2022, 18, 466-475.	4.9	25
1078	Recommendations of scRNA-seq Differential Gene Expression Analysis Based on Comprehensive Benchmarking. Life, 2022, 12, 850.	1.1	4
1079	Thinking outside the box: non-canonical targets in multiple sclerosis. Nature Reviews Drug Discovery, 2022, 21, 578-600.	21.5	31
1080	The Seasonal Fluctuation of Fatigue in Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	7
1081	Protocol for the treatment of patients with multiple sclerosis using bone marrow stromal cells (BMSC) in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine". Ukrains Kyi Visnyk Psykhonevrolohii, 2022, , 85-90.	0.0	0
1082	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	17
1083	Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
1084	Fatty acids role in multiple sclerosis as â€œmetabokinesâ€• Journal of Neuroinflammation, 2022, 19, .	3.1	20

#	Article	IF	Citations
1085	Humanized Anti-RGMa Antibody Treatment Promotes Repair of Blood-Spinal Cord Barrier Under Autoimmune Encephalomyelitis in Mice. Frontiers in Immunology, 0, 13, .	2.2	1
1086	Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases. Frontiers in Neurology, 0, 13, .	1.1	6
1087	Impact on quality of life in multiple sclerosis patients: Which urinary symptoms are to blame?. Progres En Urologie, 2022, 32, 711-716.	0.3	3
1088	Reparative inflammation in multiple sclerosis. Seminars in Immunology, 2022, 59, 101630.	2.7	2
1089	Microglia in multiple sclerosis â€“ pathogenesis and imaging. Current Opinion in Neurology, 2022, 35, 299-306.	1.8	17
1090	Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review. Neurology International, 2022, 14, 506-535.	1.3	14
1091	Do patientsâ€™ and referral centersâ€™ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurological Sciences, 0, , .	0.9	1
1092	Lanthionine Ketimine Ethyl Ester Accelerates Remyelination in a Mouse Model of Multiple Sclerosis. ASN Neuro, 2022, 14, 175909142211123.	1.5	2
1093	Sensitivity of portable low-field magnetic resonance imaging for multiple sclerosis lesions. NeuroImage: Clinical, 2022, 35, 103101.	1.4	18
1094	Erectile Dysfunction in Multiple Sclerosis: A Prevalence Meta-Analysis and Systematic Review. Journal of Sexual Medicine, 2022, 19, 1255-1268.	0.3	2
1095	Microglia Regulate Bloodâ€“Brain Barrier Integrity via MiRâ€126aâ€5p/MMP9 Axis during Inflammatory Demyelination. Advanced Science, 2022, 9, .	5.6	14
1096	Analysis of the entire mitochondrial genome reveals Leberâ€™s hereditary optic neuropathy mitochondrial DNA mutations in an Arab cohort with multiple sclerosis. Scientific Reports, 2022, 12, .	1.6	1
1097	Looking Beyond Physical Disability: Cognitive Impairment in Persons With Multiple Sclerosis. Rehabilitation Nursing, 0, Publish Ahead of Print, .	0.3	0
1098	Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES. Multiple Sclerosis Journal, 2022, 28, 1324-1326.	1.4	1
1099	Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4551-4566.	3.3	3
1101	Unveiling Leukocyte Extracellular Traps in Inflammatory Responses of the Central Nervous System. Frontiers in Immunology, 0, 13, .	2.2	1
1102	Contribution of B cells to cortical damage in multiple sclerosis. Brain, 2022, 145, 3363-3373.	3.7	15
1103	Integrated Analysis and Identification of CSF-Derived Risk miRNAs and Pivotal Genes in Multiple Sclerosis. Journal of Molecular Neuroscience, 2022, 72, 1916-1928.	1.1	4

#	Article	IF	Citations
1104	Gut microbiota: a new insight into neurological diseases. Chinese Medical Journal, 2023, 136, 1261-1277.	0.9	8
1105	Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics, 2022, 14, 1420.	2.0	3
1106	Ginsenoside Rg1 promotes remyelination and functional recovery in demyelinating disease by enhancing oligodendrocyte precursor cells-mediated myelin repair. Phytomedicine, 2022, 106, 154309.	2.3	5
1107	An antagonistic monoclonal antiâ€“Plexin-B1 antibody exerts therapeutic effects in mouse models of postmenopausal osteoporosis and multiple sclerosis. Journal of Biological Chemistry, 2022, 298, 102265.	1.6	3
1108	Effects of Acceptance and Commitment Therapy (ACT) and Mindfulness-Based Stress Reduction (MBSR) on symptoms and emotional competencies in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 67, 104029.	0.9	4
1109	Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis. Biomedicines, 2022, 10, 1629.	1.4	3
1110	Intermittent calorie restriction alters T cell subsets and metabolic markers in people with multiple sclerosis. EBioMedicine, 2022, 82, 104124.	2.7	29
1112	Multiple sclerosis and neuromyelitis optica spectrum disorders. , 2023, , 575-608.		1
1113	Consensus on early detection of disease progression in patients with multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	3
1114	Inhibition of astrocytic DRD2 suppresses CNS inflammation in an animal model of multiple sclerosis. Journal of Experimental Medicine, 2022, 219, .	4.2	8
1115	Impact of Multiple Sclerosis Risk Polymorphism rs7665090 on MANBA Activity, Lysosomal Endocytosis, and Lymphocyte Activation. International Journal of Molecular Sciences, 2022, 23, 8116.	1.8	4
1116	Unraveling the Influence of HHEX Risk Polymorphism rs7923837 on Multiple Sclerosis Pathogenesis. International Journal of Molecular Sciences, 2022, 23, 7956.	1.8	2
1117	High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
1118	Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. EBioMedicine, 2022, 82, 104179.	2.7	17
1119	Brain atrophy measurement over a MRI scanner change in multiple sclerosis. NeuroImage: Clinical, 2022, 36, 103148.	1.4	3
1120	Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review. Arquivos De Neuro-Psiquiatria, 2022, 80, 173-181.	0.3	1
1121	Expression of antioxidant enzymes in lesions of multiple sclerosis and its models. Scientific Reports, 2022, 12, .	1.6	5
1122	Angle-Angle Diagrams in the Assessment of Locomotion in Persons with Multiple Sclerosis: A Preliminary Study. Applied Sciences (Switzerland), 2022, 12, 7223.	1.3	1

#	Article	IF	Citations
1123	Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 9583.	1.8	11
1125	The effectiveness of Pythagorean self-awareness intervention in improving the quality of sexual life of women with multiple sclerosis. Journal of Shahrekord University of Medical Sciences, 2022, 24, 127-132.	0.1	0
1126	Neuroimmune signaling at the brain borders. Immunological Reviews, 2022, 311, 9-25.	2.8	6
1127	Angiogenesis and Multiple Sclerosis Pathogenesis: A Glance at New Pharmaceutical Approaches. Journal of Clinical Medicine, 2022, 11, 4643.	1.0	3
1128	Interferon-Î² Decreases the Hypermetabolic State of Red Blood Cells from Patients with Multiple Sclerosis. ACS Chemical Neuroscience, 2022, 13, 2658-2665.	1.7	1
1129	Infectious mononucleosis is associated with an increased incidence of multiple sclerosis: Results from a cohort study of 32,116 outpatients in Germany. Frontiers in Immunology, 0, 13, .	2.2	13
1130	DoenÃ§as Desmielinizantes do Sistema Nervoso Central: estado da arte baseado em uma revisÃ£o integrativa. Brazilian Journal of Case Reports, 2022, 2, 136-147.	0.0	0
1132	Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis. Immunology, 2023, 168, 152-169.	2.0	3
1133	Advanced diffusion MRI and image texture analysis detect widespread brain structural differences between relapsing-remitting and secondary progressive multiple sclerosis. Frontiers in Human Neuroscience, 0, 16, .	1.0	1
1134	Adult-Onset Genetic Central Nervous System Disorders Masquerading as Acquired Neuroinflammatory Disorders. JAMA Neurology, 2022, 79, 1069.	4.5	11
1135	Role of Cytokines, Chemokines and IFN-Î³+ IL-17+ Double-Positive CD4+ T Cells in Patients with Multiple Sclerosis. Biomedicines, 2022, 10, 2062.	1.4	5
1136	CSF Î²-amyloid is not a prognostic marker in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 68, 104096.	0.9	2
1137	Promoting remyelination: A case study in regenerative medicine. Current Opinion in Chemical Biology, 2022, 70, 102201.	2.8	4
1138	The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica. Autoimmunity Reviews, 2022, 21, 103170.	2.5	1
1139	Associated factors of potential drug-drug interactions and drugâ€“food interactions in patients with multiple sclerosis. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211083.	1.1	4
1140	Clinical application of transcranial magnetic stimulation in multiple sclerosis. Frontiers in Immunology, 0, 13, .	2.2	4
1141	Multiple Sclerosis and related disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, , 177-200.	1.0	4
1142	The sequential natalizumab â€“ alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial â€“ Part I: Rationale and objectives. Journal of Central Nervous System Disease, 2022, 14, 117957352211239.	0.7	0

#	Article	IF	Citations
1143	Dysfunction of the oligodendrocytes in amyotrophic lateral sclerosis. Journal of Biomedical Research, 2022, 36, 336.	0.7	5
1144	Neuroinflammation in Multiple Sclerosis. , 2022, , .		0
1145	Cortical lesions, central vein sign, and paramagnetic rim lesions in multiple sclerosis: Emerging machine learning techniques and future avenues. NeuroImage: Clinical, 2022, 36, 103205.	1.4	12
1146	Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity. SSRN Electronic Journal, 0, , .	0.4	0
1147	Acupuncture Treatment for Multiple Sclerosis. , 2022, , 565-591.		0
1148	Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD). International Review of Neurobiology, 2022, , 129-178.	0.9	2
1149	Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina. Arquivos De Neuro-Psiquiatria, 2022, 80, 699-705.	0.3	0
1150	The RING finger protein family in health and disease. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	31
1151	Breastfeeding and Risk of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Observational Studies. Neuroepidemiology, 2022, 56, 391-401.	1.1	2
1152	Outcomes and Health Care Service Use in People 50 Years or Older With and Without Multiple Sclerosis: A 6-Year Observational Analysis. International Journal of MS Care, 2022, , .	0.4	0
1153	Comprehensive Bioinformatics Analysis Combined with Wet-Lab Experiments to Find Target Proteins of Chinese Medicine Monomer. Molecules, 2022, 27, 6105.	1.7	0
1154	Polymorphisms in ARNTL/BMAL1 and CLOCK Are Not Associated with Multiple Sclerosis in Spanish Population. Biology, 2022, 11, 1417.	1.3	1
1156	Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Frontiers in Immunology, 0, 13, .	2.2	21
1157	Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2263-2273.	1.4	3
1158	Transcriptional abnormalities in induced pluripotent stem cell-derived oligodendrocytes of individuals with primary progressive multiple sclerosis. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	2
1159	Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic. Scientific Reports, 2022, 12, .	1.6	4
1161	Astrocytes show increased levels of Ero1Î± in multiple sclerosis and its experimental autoimmune encephalomyelitis animal model. European Journal of Neuroscience, 2022, 56, 5177-5190.	1.2	0
1162	The role of machine learning in developing non-magnetic resonance imaging based biomarkers for multiple sclerosis: aÂsystematicÂreview. BMC Medical Informatics and Decision Making, 2022, 22, .	1.5	9

#	Article	IF	Citations
1163	Astrocytic SARM1 promotes neuroinflammation and axonal demyelination in experimental autoimmune encephalomyelitis through inhibiting GDNF signaling. Cell Death and Disease, 2022, 13, .	2.7	7
1164	IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes. Journal of Neuroinflammation, 2022, 19, .	3.1	6
1165	Machine learning corroborates subjective ratings of walking and balance difficulty in multiple sclerosis. Frontiers in Artificial Intelligence, 0, 5, .	2.0	3
1166	Community Awareness Toward Multiple Sclerosis in the Western Region of Saudi Arabia: A Cross-Sectional Study. Cureus, 2022, , .	0.2	0
1167	Tear Biomarkers in Alzheimerâ€™s and Parkinsonâ€™s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review). International Journal of Molecular Sciences, 2022, 23, 10123.	1.8	14
1168	SIRT1 inactivation switches reactive astrocytes to an antiinflammatory phenotype in CNS autoimmunity. Journal of Clinical Investigation, 2022, 132, .	3.9	12
1169	Safety and efficacy of tyrosine kinase inhibitors for the treatment of multiple sclerosis: A systematic review and meta-analysis from randomized controlled trials. Frontiers in Neurology, 0, 13, .	1.1	1
1171	Cross-regional homeostatic and reactive glial signatures in multiple sclerosis. Acta Neuropathologica, 2022, 144, 987-1003.	3.9	14
1172	Medication habits among persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104224.	0.9	2
1173	Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104209.	0.9	7
1174	Bladder dysfunction in experimental autoimmune encephalomyelitis reflects clinical severity: A pilot study. Journal of Neuroimmunology, 2022, 372, 577973.	1.1	3
1175	TRACking health behaviors in people with Multiple Sclerosis (TRAC-MS): Study protocol and description of the study sample. Contemporary Clinical Trials Communications, 2022, 30, 101006.	0.5	1
1176	Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience. Journal of Central Nervous System Disease, 2022, 14, 117957352211354.	0.7	0
1177	Significance of Mitochondrial Dysfunction in the Progression of Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 12725.	1.8	8
1178	Prior optic neuritis detection on peripapillary ring scans using deep learning. Annals of Clinical and Translational Neurology, 2022, 9, 1682-1691.	1.7	2
1179	Activation of TRPV1 receptor facilitates myelin repair following demyelination via the regulation of microglial function. Acta Pharmacologica Sinica, 2023, 44, 766-779.	2.8	5
1180	Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study. Neurological Sciences, 2023, 44, 685-691.	0.9	1
1181	Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis. Neurologic Clinics, 2023, 41, 87-106.	0.8	3

#	Article	IF	Citations
1182	Controversias en neuroinmunologÃa: esclerosis mÃºltiple, vacunaciÃ³n, SARS-CoV-2 y otros dilemas. Biomedica, 2022, 42, 78-99.	0.3	0
1183	Neuron Protection by EDTA May Explain the Successful Outcomes of Toxic Metal Chelation Therapy in Neurodegenerative Diseases. Biomedicines, 2022, 10, 2476.	1.4	6
1185	The Psychosocial Impact of Parental Multiple Sclerosis on Children and Adolescents: A Systematic Review. International Journal of MS Care, 2023, 25, 63-70.	0.4	2
1186	The Effect of Exercise Training and Royal Jelly on Hippocampal Cannabinoid-1-Receptors and Pain Threshold in Experimental Autoimmune Encephalomyelitis in Rats as Animal Model of Multiple Sclerosis. Nutrients, 2022, 14, 4119.	1.7	4
1187	A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. Biomedicines, 2022, 10, 2604.	1.4	6
1188	Correlation between the Neutrophil-to-Lymphocyte Ratio and Multiple Sclerosis: Recent Understanding and Potential Application Perspectives. Neurology Research International, 2022, 2022, 1-10.	0.5	5
1189	Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing. Frontiers in Immunology, 0, 13, .	2.2	5
1190	Single-Cell Analysis to Better Understand the Mechanisms Involved in MS. International Journal of Molecular Sciences, 2022, 23, 12142.	1.8	2
1191	Heterogeneity and regulation of oligodendrocyte morphology. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
1192	Rethinking the MS brain: Synaptic loss and computational modelling of brain networks. Multiple Sclerosis Journal, 2022, 28, 1999-2000.	1.4	0
1193	Characteristics of cerebral blood flow in an Eastern sample of multiple sclerosis patients: A potential quantitative imaging marker associated with disease severity. Frontiers in Immunology, 0, 13, .	2.2	0
1194	Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	1
1195	Physiotherapy for Multiple Sclerosis Patients From Early to Transition Phase: A Scoping Review. Cureus, 2022, , .	0.2	0
1196	Prophylactic effects of cucurbitacin B in the EAE Model of multiple sclerosis by adjustment of STAT3/IL-23/IL-17 axis and improvement of neuropsychological symptoms. Metabolic Brain Disease, 2022, 37, 2937-2953.	1.4	3
1197	Microbial dysbiosis in the gut drives systemic autoimmune diseases. Frontiers in Immunology, 0, 13, .	2.2	30
1198	Disease-modifying treatment patterns among multiple sclerosis patients: a Brazilian descriptive study. Revista Neurociencias, 0, 30, 1-22.	0.0	0
1199	Association of Polyunsaturated Fatty Acid Intake on Inflammatory Gene Expression and Multiple Sclerosis: A Systematic Review and Meta-Analysis. Nutrients, 2022, 14, 4627.	1.7	6
1201	Neurofilaments contribution in clinic: state of the art. Frontiers in Aging Neuroscience, 0, 14, .	1.7	9

#	Article	IF	Citations
1202	Multi-omics analysis of magnetically levitated plasma biomolecules. Biosensors and Bioelectronics, 2022, , 114862.	5.3	2
1203	Subjective cognitive impairment is related to work status in people with multiple sclerosis. IBRO Neuroscience Reports, 2022, 13, 513-522.	0.7	2
1204	Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	0
1205	Argentinean consensus recommendations for the use of telemedicine in clinical practice in adult people with multiple sclerosis. Neurological Sciences, 0, , .	0.9	0
1206	MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes. Brain, 2023, 146, 1483-1495.	3.7	9
1208	CNS remyelination and inflammation: From basic mechanisms to therapeutic opportunities. Neuron, 2022, 110, 3549-3565.	3.8	31
1209	Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	10
1210	B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximab. Multiple Sclerosis and Related Disorders, 2022, 68, 104218.	0.9	1
1211	Research progress of single-cell transcriptome sequencing in autoimmune diseases and autoinflammatory disease: A review. Journal of Autoimmunity, 2022, 133, 102919.	3.0	10
1212	Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study. Multiple Sclerosis and Related Disorders, 2022, 68, 104246.	0.9	3
1213	Targeting B cell dysregulation with emerging therapies in autoimmune demyelinating disorders. Current Opinion in Neurobiology, 2022, 77, 102643.	2.0	0
1214	Mapping the Literature on Diet and Multiple Sclerosis: A Data-Driven Approach. Nutrients, 2022, 14, 4820.	1.7	3
1215	<scp>hnRNP A1</scp> dysfunction in oligodendrocytes contributes to the pathogenesis of multiple sclerosis. Glia, 2023, 71, 633-647.	2.5	6
1216	Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review. Journal of Neurology, 2023, 270, 1178-1186.	1.8	1
1217	Microglial cells: Sensors for neuronal activity and microbiota-derived molecules. Frontiers in Immunology, 0, 13, .	2.2	6
1218	Immunosenescence in Neurological Diseasesâ€"Is There Enough Evidence?. Biomedicines, 2022, 10, 2864.	1.4	2
1219	What do animal models tell us about the role of EBV in the pathogenesis of multiple sclerosis?. Frontiers in Immunology, 0, 13, .	2.2	2
1220	High-Efficacy Therapies for Treatment-NaÃ¯ve Individuals with Relapsingâ€"Remitting Multiple Sclerosis. CNS Drugs, 2022, 36, 1285-1299.	2.7	20

#	Article	IF	Citations
1221	Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	42
1222	Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve. Scientific Reports, 2022, 12, .	1.6	18
1223	Shared decision-making in patients with multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	4
1224	Rapid wholeâ€brain myelin imaging with selective inversion recovery and compressed <scp>SENSE</scp>. Magnetic Resonance in Medicine, 0, , .	1.9	1
1225	Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurology and Therapy, 2023, 12, 25-37.	1.4	5
1226	Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia. Journal of Controlled Release, 2023, 353, 675-684.	4.8	24
1227	Development of Bayesian Network for Multiple Sclerosis Risk Factor Interaction Analysis. Lecture Notes in Computer Science, 2022, , 13-24.	1.0	0
1228	R-Ras1 and R-Ras2 mice as models for investigating multiple sclerosis. , 2023, , 369-376.		0
1229	Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study. Multiple Sclerosis and Related Disorders, 2023, 69, 104455.	0.9	6
1230	Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients. Biomaterials, 2023, 292, 121930.	5.7	3
1231	Drug repurposing of ilepcimide that ameliorates experimental autoimmune encephalomyelitis via restricting inflammatory response and oxidative stress. Toxicology and Applied Pharmacology, 2023, 458, 116328.	1.3	2
1232	AssociaÃ§Ã£o entre o nÃºmero de deglutiÃ§Ãµes, resÃduo farÃngeo e broncoaspiraÃ§Ã£o na esclerose mÃºltipla. Audiology: Communication Research, 0, 27, .	0.1	0
1233	Association between the number of swallowing, pharyngeal residue and bronchopulmonary aspiration in multiple sclerosis. Audiology: Communication Research, 0, 27, .	0.1	0
1234	Radiochemical Synthesis and Evaluation of 3-[¹¹C]Methyl-4-aminopyridine in Rodents and Nonhuman Primates for Imaging Potassium Channels in the CNS. ACS Chemical Neuroscience, 2022, 13, 3342-3351.	1.7	2
1235	Multiple sclerosis clinical decision support system based on projection to reference datasets. Annals of Clinical and Translational Neurology, 2022, 9, 1863-1873.	1.7	3
1236	Cell-free DNA-based liquid biopsies in neurology. Brain, 2023, 146, 1758-1774.	3.7	19
1237	Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients. Brain Sciences, 2022, 12, 1595.	1.1	3
1238	Associations of <scp>sNfL</scp> with clinicoâ€radiological measures in a large <scp>MS</scp> population. Annals of Clinical and Translational Neurology, 2023, 10, 84-97.	1.7	9

#	Article	IF	Citations
1239	Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	12
1240	Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, e200062.	3.1	3
1241	Brain proteomeâ€wide association study linkingâ€genes in multiple sclerosis pathogenesis. Annals of Clinical and Translational Neurology, 0, , .	1.7	2
1242	Effect of puberty on the immune system: Relevance to multiple sclerosis. Frontiers in Pediatrics, 0, 10, .	0.9	7
1243	Functions and dysfunctions of oligodendrocytes in neurodegenerative diseases. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	5
1244	Redox State of Human Serum Albumin in Multiple Sclerosis: A Pilot Study. International Journal of Molecular Sciences, 2022, 23, 15806.	1.8	3
1245	Sex differences in the inflammatory response of the mouse DRG and its connection to pain in experimental autoimmune encephalomyelitis. Scientific Reports, 2022, 12, .	1.6	4
1246	Mitochondrial DNA haplogroup analysis in Saudi Arab patients with multiple sclerosis. PLoS ONE, 2022, 17, e0279237.	1.1	0
1248	Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis. Multiple Sclerosis Journal, 2023, 29, 702-718.	1.4	1
1249	Research advances in cGASâ€“stimulator of interferon genes pathway and central nervous system diseases: Focus on new therapeutic approaches. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	5
1250	Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis. Annals of Clinical and Translational Neurology, 2023, 10, 166-180.	1.7	4
1251	Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naÃ¯ve multiple sclerosis. Journal of Neuroinflammation, 2022, 19, .	3.1	2
1252	Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis. Journal of Neurology, 2023, 270, 1624-1636.	1.8	4
1253	Quantitative susceptibility mapping of the normal-appearing white matter as a potential new marker of disability progression in multiple sclerosis. European Radiology, 2023, 33, 5368-5377.	2.3	3
1254	Neurological complications of COVID-19. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 161-180.	0.2	8
1255	Psychophysical Evaluation of Visual vs. Computerâ€Aided Detection of Brain Lesions on Magnetic Resonance Images. Journal of Magnetic Resonance Imaging, 2023, 58, 642-649.	1.9	2
1256	Huperzineâ€”A Improved Animal Behavior in Cuprizone-Induced Mouse Model by Alleviating Demyelination and Neuroinflammation. International Journal of Molecular Sciences, 2022, 23, 16182.	1.8	5
1257	Tissue-resident immune cells in the pathogenesis of multiple sclerosis. Inflammation Research, 2023, 72, 363-372.	1.6	0

#	Article	IF	Citations
1258	Pharmacokineticâ€Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical Pharmacology and Therapeutics, 2023, 113, 692-703.	2.3	1
1259	Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges. Pharmaceutics, 2023, 15, 298.	2.0	6
1260	The gut microbiota in multiple sclerosis varies with disease activity. Genome Medicine, 2023, 15, .	3.6	23
1261	Retinal ganglion cell loss is associated with future disability worsening in early relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2023, 30, 982-990.	1.7	2
1262	Synapse Dysfunctions in Multiple Sclerosis. International Journal of Molecular Sciences, 2023, 24, 1639.	1.8	5
1263	Interleukin-4 as a therapeutic target. , 2023, 242, 108348.		10
1264	Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge. Neurological Sciences, 2023, 44, 1141-1146.	0.9	3
1265	The repertoire of CSF antiviral antibodies in patients with neuroinflammatory diseases. Science Advances, 2023, 9, .	4.7	1
1266	Leukocyte Telomere Length Predicts Severe Disability in Relapsing-Remitting Multiple Sclerosis and Correlates with Mitochondrial DNA Copy Number. International Journal of Molecular Sciences, 2023, 24, 916.	1.8	3
1267	Assessment of intelligence quotient in patients with neuromyelitis optica spectrum disease and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 70, 104492.	0.9	0
1268	Neuro rehabilitation effectiveness based on virtual reality and tele rehabilitation in people with multiple sclerosis in Argentina: Reavitelem study. Multiple Sclerosis and Related Disorders, 2023, 70, 104499.	0.9	2
1269	Chinese herbal medicine for people with multiple sclerosis: Protocol for a systematic review and meta-analysis. European Journal of Integrative Medicine, 2023, 58, 102220.	0.8	1
1270	B Cells Drive MHC Class Iâ€“Restricted CD4 T Cells to Induce Spontaneous Central Nervous System Autoimmunity. Journal of Immunology, 2022, 209, 1880-1891.	0.4	2
1272	Identification of ferroptosis-related gene signatures associated with multiple sclerosis using weighted gene co-expression network analysis. Medicine (United States), 2022, 101, e31802.	0.4	3
1273	Automatic detection of active and inactive multiple sclerosis plaques using the Bayesian approach in susceptibility-weighted imaging. Acta Radiologica, 0, , 028418512211430.	0.5	0
1274	Fittsâ€™ Tapping Task as a New Test for Cognition and Manual Dexterity in Multiple Sclerosis: Validation Study. Medicina (Lithuania), 2023, 59, 29.	0.8	0
1275	Therapeutic potential of blocking GAPDH nitrosylation with CGP3466b in experimental autoimmune encephalomyelitis. Frontiers in Neurology, 0, 13, .	1.1	1
1276	Posttranscriptional Regulation of Gene Expression Participates in the Myelin Restoration in Mouse Models of Multiple Sclerosis: Antisense Modulation of HuR and HuD ELAV RNA Binding Protein. Molecular Neurobiology, 2023, 60, 2661-2677.	1.9	3

#	Article	IF	Citations
1277	Neutrophil-to-Lymphocyte Ratio: a Marker of Neuro-inflammation in Multiple Sclerosis Patients: a Meta-analysis and Systematic Review. SN Comprehensive Clinical Medicine, 2023, 5, .	0.3	0
1278	Neuron-oligodendrocyte potassium shuttling at nodes of Ranvier protects against inflammatory demyelination. Journal of Clinical Investigation, 2023, 133, .	3.9	4
1279	Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology. Biomedicines, 2023, 11, 328.	1.4	4
1280	Bacillus amyloliquifaciens-Supplemented Camel Milk Suppresses Neuroinflammation of Autoimmune Encephalomyelitis in a Mouse Model by Regulating Inflammatory Markers. Nutrients, 2023, 15, 550.	1.7	7
1281	Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders. Frontiers in Immunology, 0, 13, .	2.2	3
1283	Ultrasound-Guided Percutaneous Neuromodulation in Multiple Sclerosis: A Case Report. Degenerative Neurological and Neuromuscular Disease, 0, Volume 13, 15-20.	0.7	1
1284	Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 71, 104545.	0.9	1
1285	Multiple Sclerosis: Inflammatory and Neuroglial Aspects. Current Issues in Molecular Biology, 2023, 45, 1443-1470.	1.0	10
1286	A comparison between optimized PLGA and CS-Alg-PLGA microspheres for long-lasting release of glatiramer acetate. Journal of Drug Delivery Science and Technology, 2023, 82, 104355.	1.4	3
1287	Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology, 2023, 19, 289-304.	4.9	30
1288	Potential biological contributers to the sex difference in multiple sclerosis progression. Frontiers in Immunology, 0, 14, .	2.2	3
1289	Training reactive balance using trips and slips in people with multiple sclerosis: A blinded randomised controlled trial. Multiple Sclerosis and Related Disorders, 2023, 73, 104607.	0.9	1
1290	Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results. Multiple Sclerosis and Related Disorders, 2023, 73, 104677.	0.9	2
1291	Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 74, 104706.	0.9	3
1292	High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial. EClinicalMedicine, 2023, 59, 101957.	3.2	6
1293	Pathways to healing: Plants with therapeutic potential for neurodegenerative diseases. IBRO Neuroscience Reports, 2023, 14, 210-234.	0.7	4
1294	Efficacy of ultraviolet B radiation versus vitamin D3 on postural control and cognitive functions in relapsing-remitting multiple sclerosis: A randomized controlled study. Journal of Bodywork and Movement Therapies, 2023, , .	0.5	0
1295	Mobile apps used for people living with multiple sclerosis: A scoping review. Multiple Sclerosis and Related Disorders, 2023, 73, 104628.	0.9	6

#	Article	IF	Citations
1298	Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression. Clinical Neurology and Neurosurgery, 2023, 225, 107612.	0.6	3
1299	Change in Insomnia and Depressive Symptoms During COVID-19: A Prospective Longitudinal Study of Iranian Women with Multiple Sclerosis. Behavioral Sleep Medicine, 2023, 21, 741-756.	1.1	0
1300	Multiple sclerosis and circadian rhythms: Can diet act as a treatment?. Acta Physiologica, 2023, 237, .	1.8	5
1301	Specific alterations in NKG2D+ T lymphocytes in relapsing-remitting and progressive multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2023, 71, 104542.	0.9	2
1302	Multiple Sklerose. , 2022, , 497-517.		0
1303	Interpretations of healthy eating after a diagnosis of multiple sclerosis: a secondary qualitative analysis. British Food Journal, 2023, 125, 2918.	1.6	0
1304	Pharmacological treatment promoting remyelination enhances motor function after internal capsule demyelination in mice. Neurochemistry International, 2023, 164, 105505.	1.9	3
1305	Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis. Diagnostics, 2023, 13, 596.	1.3	1
1306	Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection. Radiology, 2023, 307, .	3.6	6
1307	Predictors of severity and outcome of multiple sclerosis relapses. BMC Neurology, 2023, 23, .	0.8	4
1308	ATR-FTIR spectroscopy of plasma supported by multivariate analysis discriminates multiple sclerosis disease. Scientific Reports, 2023, 13, .	1.6	1
1309	Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients. NeuroImage: Clinical, 2023, 37, 103349.	1.4	0
1310	Reduced secretion of LCN2 (lipocalin 2) from reactive astrocytes through autophagic and proteasomal regulation alleviates inflammatory stress and neuronal damage. Autophagy, 2023, 19, 2296-2317.	4.3	7
1311	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. Heliyon, 2023, 9, e13725.	1.4	0
1312	FATIGUE IN MULTIPLE SCLEROSIS. Eastern Ukrainian Medical Journal, 2022, 10, 309-317.	0.0	0
1313	A Unique Multiplex ELISA to Profile Growth Factors and Cytokines in Cerebrospinal Fluid. Methods in Molecular Biology, 2023, , 157-168.	0.4	0
1314	Therapeutic potential of extracellular vesicles in neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 243-266.	1.0	5
1315	Higher throughput workflow with sensitive, reliable and automatic quantification of myelination in vitro suitable for drug screening. Scientific Reports, 2023, 13, .	1.6	0

#	Article	IF	Citations
1316	Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging. Multiple Sclerosis and Related Disorders, 2023, 71, 104572.	0.9	1
1317	Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain. PharmacoEconomics - Open, 2023, 7, 431-441.	0.9	2
1318	Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023, 9, 205521732311547.	0.5	0
1319	Intermittent fasting and immunomodulatory effects: A systematic review. Frontiers in Nutrition, 0, 10, .	1.6	4
1320	ANGPTL2 binds MAG to efficiently enhance oligodendrocyte differentiation. Cell and Bioscience, 2023, 13, .	2.1	2
1321	Mechanisms of antigen-induced reversal of CNS inflammation in experimental demyelinating disease. Science Advances, 2023, 9, .	4.7	1
1323	Inflammatory Cytokines Associated with Multiple Sclerosis Directly Induce Alterations of Neuronal Cytoarchitecture in Human Neurons. Journal of NeuroImmune Pharmacology, 2023, 18, 145-159.	2.1	3
1324	Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Frontiers in Neurology, 0, 14, .	1.1	10
1325	Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review. International Journal of Environmental Research and Public Health, 2023, 20, 4624.	1.2	17
1327	Microglia activation in central nervous system disorders: A review of recent mechanistic investigations and development efforts. Frontiers in Neurology, 0, 14, .	1.1	8
1328	Metabolic costs of walking and arm reaching in persons with mild multiple sclerosis. Journal of Neurophysiology, 2023, 129, 819-832.	0.9	2
1329	B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Frontiers in Immunology, 0, 14, .	2.2	7
1330	Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment. Frontiers in Neuroscience, 0, 17, .	1.4	0
1331	Infections among individuals with multiple sclerosis, Alzheimerâ€™s disease and Parkinsonâ€™s disease. Brain Communications, 2023, 5, .	1.5	2
1332	The role of plasma cortisol in dementia, epilepsy, and multiple sclerosis: A Mendelian randomization study. Frontiers in Endocrinology, 0, 14, .	1.5	5
1333	FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple sclerosis. CNS Neuroscience and Therapeutics, 2023, 29, 1497-1511.	1.9	6
1334	Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis. Journal of Neurology, 2023, 270, 3213-3224.	1.8	3
1335	Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases. International Journal of Molecular Sciences, 2023, 24, 5925.	1.8	4

#	Article	IF	Citations
1336	Evaluation of benzoylacetonitriles as novel anti-neuroinflammatory agents. Medicinal Chemistry Research, 2023, 32, 802-807.	1.1	0
1337	C1q and central nervous system disorders. Frontiers in Immunology, 0, 14, .	2.2	3
1338	Microglial aryl hydrocarbon receptor enhances phagocytic function via SYK and promotes remyelination in the cuprizone mouse model of demyelination. Journal of Neuroinflammation, 2023, 20, .	3.1	3
1339	Double inversion recovery to detect cervical spinal cord multiple sclerosis lesions. Journal of Neuroimaging, 0, , .	1.0	0
1340	Droplet-based forward genetic screening of astrocyteâ€“microglia cross-talk. Science, 2023, 379, 1023-1030.	6.0	35
1341	Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis. International Journal of Molecular Sciences, 2023, 24, 6373.	1.8	2
1342	Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting. Cell, 2023, 186, 1309-1327.	13.5	40
1343	A distinctive IgG-mediated pathogenesis for primary progressive multiple sclerosis?. Brain, 0, , .	3.7	0
1344	Exploring physiciansâ€™ prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods. BMC Neurology, 2023, 23, .	0.8	0
1346	Multiplex Analysis of Cerebrospinal Fluid and Serum Exosomes MicroRNAs of Untreated Relapsing Remitting Multiple Sclerosis (RRMS) and Proposing Noninvasive Diagnostic Biomarkers. NeuroMolecular Medicine, 2023, 25, 402-414.	1.8	4
1347	Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns. Pharmaceutics, 2023, 15, 1151.	2.0	1
1348	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€“ Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 2023, 38, 77-278.	0.7	81
1349	MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis. Current Neuropharmacology, 2023, 21, 2567-2582.	1.4	2
1350	The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review. Cellular and Molecular Neurobiology, 2023, 43, 2643-2673.	1.7	7
1351	Development and pilot testing of an occupational therapy intervention program based on Occupational Adaptation Model for caregivers of people with multiple sclerosis. British Journal of Occupational Therapy, 2023, 86, 423-431.	0.5	1
1352	Lactate metabolism in neurodegenerative diseases. Neural Regeneration Research, 2024, 19, 69-74.	1.6	6
1354	Functional and structural readouts for early detection of retinal involvement in multiple sclerosis. Frontiers in Integrative Neuroscience, 0, 17, .	1.0	0
1355	Common pathogenetic mechanisms in affective disorders and multiple sclerosis: role of interleukin imbalance in the progression of comorbid pathology. Vestnik Nevrologii, Psihiatrii I Nejrohirurgii, 2023, , 270-281.	0.0	0

#	Article	IF	Citations
1356	Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices. Patient, 0, , .	1.1	0
1357	Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis. Frontiers in Immunology, 0, 14, .	2.2	3
1358	Top Ten Tips Palliative Care Clinicians Should Know about Multiple Sclerosis. Journal of Palliative Medicine, 2023, 26, 1555-1561.	0.6	1
1359	Influence of Epstein-Barr virus infection on developing multiple sclerosis. Journal of Education, Health and Sport, 2023, 22, 46-55.	0.0	0
1360	Health Disparities in Multiple Sclerosis among Hispanic and Black Populations in the United States. Biomedicines, 2023, 11, 1227.	1.4	2
1361	In vivo MRI is sensitive to remyelination in a nonhuman primate model of multiple sclerosis. ELife, 0, 12, .	2.8	1
1376	Functional MRI of Multiple Sclerosis. , 2023, , 781-798.		0
1381	Roles and regulation of microglia activity in multiple sclerosis: insights from animal models. Nature Reviews Neuroscience, 2023, 24, 397-415.	4.9	10
1393	Protective role of natural products and bioactive compounds in multiple sclerosis. , 2023, , 453-482.		0
1399	The neuroimmunology of fatigue in multiple sclerosis. , 2023, , 55-72.		0
1427	Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives. Clinical and Experimental Medicine, 2023, 23, 3321-3338.	1.9	2
1428	Implications of immunometabolism for smouldering MS pathology and therapy. Nature Reviews Neurology, 0, , .	4.9	0
1433	Neuroprotective effects of flavonoids. , 2023, , 133-200.		1
1447	Rhombomere 5 r5. , 2023, , 313-336.		0
1474	The Role of Clinical Assessment in the Era of Biomarkers. Neurotherapeutics, 2023, 20, 1001-1018.	2.1	1
1481	Astrocytes in human central nervous system diseases: a frontier for new therapies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	15
1494	Clinical characteristics and treatment approaches in patients with Susac syndrome: a scoping review of cases. Journal of Neurology, 2023, 270, 5719-5730.	1.8	1
1498	Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases. , 2024, , 375-400.		0

#	Article	IF	Citations
1502	Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study. Journal of Neurology, 0, , .	1.8	1
1524	Vitamin D mechanisms of protection in multiple sclerosis. , 2024, , 1129-1166.		0
1525	Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Cellular and Molecular Neurobiology, 2023, 43, 4071-4101.	1.7	0
1526	Vitamin D and the epidemiology of multiple sclerosis. , 2024, , 1167-1184.		0
1539	Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
1557	Management of Osteoporosis, Fracture and Falls in People with Multiple Sclerosis: Systematic Review of Guidelines. Calcified Tissue International, 2024, 114, 201-209.	1.5	0
1568	Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review. Cellular and Molecular Neurobiology, 2024, 44, .	1.7	0
1579	Imaging of brain barrier inflammation and brain fluid drainage in human neurological diseases. Cellular and Molecular Life Sciences, 2024, 81, .	2.4	1
1586	Treatment guidelines and considerations for pediatric multiple sclerosis. , 2024, , 207-235.		0
1588	Class Probability Distributions of a Neural Network Classifier of Multiple Sclerosis Lesions on Quantitative Susceptibility Mapping. IFMBE Proceedings, 2024, , 663-672.	0.2	0
1593	Neuroprotection induced by apigenin. , 2024, , 1241-1262.		0
1601	Neuroprotective Effects of Bromelain on the Common Neurodegenerative Diseases: A Systematic Review. Neurochemical Journal, 2023, 17, 715-726.	0.2	0
1624	Curcuminoids with Antineurodegenerative Properties: Current Trends and Future Perspectives. , 2023, , 101-125.		0
1631	Myelin Bilayer Imaging. , 2023, , 511-525.		0
1633	Multiple Sklerose. , 2023, , 531-552.		0